



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/705, G01N 33/68		A2	(11) International Publication Number: WO 00/70044
			(43) International Publication Date: 23 November 2000 (23.11.00)
(21) International Application Number: PCT/US00/12383 (22) International Filing Date: 8 May 2000 (08.05.00) (30) Priority Data: 60/134,063 13 May 1999 (13.05.99) US 60/137,547 4 June 1999 (04.06.99) US (71) Applicant (for all designated States except US): THE JOHNS HOPKINS UNIVERSITY [US/US]; 111 Market Place, Baltimore, MD 21201 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MITTMAN, Scott [US/US]; The Johns Hopkins University, 111 Market Place, Baltimore, MD 21201 (US). AGNEW, William, S. [US/US]; The Johns Hopkins University, 111 Market Place, Baltimore, MD 21201 (US). (74) Agents: KAGAN, Sarah, A. et al.; Banner & Witcoff, Ltd., Eleventh Floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	
(54) Title: HUMAN BRAIN T CALCIUM CHANNEL ALPHA-SUBUNIT SPLICE VARIANTS			
(57) Abstract			
<p>The structures of <i>CACNA1G</i> and <i>CACNA1I</i>, the genes encoding the human brain T Ca²⁺ channel α_{1G} and α_{1I} subunits, respectively, were determined by comparison of polymerase chain reaction-amplified brain cDNA and genomic sequences. <i>CACNA1G</i> consists of at least 38 exons spanning at least 66,490 basepairs of chromosome 17q22. Alternative splicing of the RNA occurs at six sites: cassette exons 14, 26, 34 and 35, an internal donor in exon 25 and protein-coding intron 38B. Additionally, the RNA can be polyadenylated at either of two sites. Alternative splicing of <i>CACNA1G</i> RNA may lead to expression of as many as 64 distinct protein products, ranging from 2,171 to 2,377 amino-acids residues, with as many as 45 potential phosphorylation sites. <i>CACNA1I</i> consists of at least 37 exons spanning at least 116,390 basepairs of chromosome 22q12.3-13.2. Alternative splicing of the gene occurs at three sites: cassette exon 9, an alternative acceptor in exon 33 and mutually-exclusive 3' exons 36B and 37. Alternative splicing of <i>CACNA1I</i> RNA may lead to expression of as many as 8 distinct protein products, ranging from 1,968 to 2,223 amino-acids residues, with as many as 28 potential phosphorylation sites. Molecular diversity generated by alternative splicing and post-translation modification of these and other members of the T α_1 subunit gene family may account for the observed heterogeneity of T currents in central neurons.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HUMAN BRAIN T CALCIUM CHANNEL ALPHA-SUBUNIT SPLICE VARIANTS

This invention was made using funds from the U.S. government. Under the terms of NIH grants K08NS01939 and P50HL52307, the government may retain certain rights in the invention.

TECHNICAL FIELD OF THE INVENTION

This invention is related to ion channels. In particular, it is related to ion channels related to brain function.

BACKGROUND OF THE INVENTION

Voltage-dependent calcium channels are involved in both coupling electrical activity to calcium influx and contributing to membrane properties. Low voltage-activated (LVA) calcium channels activate at potentials near the resting membrane potential. LVA participate in spike-induced calcium entry and allow calcium influx at potentials below threshold. LVA calcium channels also are involved in subthreshold membrane fluctuations. LVA calcium channel dysfunction is implicated in epileptiform activity. Moreover, these channels are targets for antiepileptic drugs.

T-type (transient) properties in neurons include low voltage activation, strongly voltage-dependent kinetics, rapid inactivation, slow deactivation, and small single-channel conductance.

Recently, a subfamily of genes (designated Ca_vT) has been discovered encoding α_1 subunits that are ~ 30% homologous to HVA subunit genes in their putative membrane-spanning regions.

T currents are a diverse class of Ca^{2+} current characterized by a low voltage threshold for activation. Proposed functions include generation of low-threshold spikes that lead to bursting, promotion of voltage oscillations, boosting of Ca^{2+} entry and synaptic potentiation. T currents may be the targets of succinimides and related compounds administered in the treatment of absence epilepsy. Recently, cDNA sequences of three T α_1 subunits, rat α_{1G} and α_{1I} and human α_{1H} , have been reported.

Ca^{2+} channel α_1 subunits are encoded by at least 10 genes falling into three subfamilies: ABE, SCDF and GHI¹. Alternative splicing of α_1 RNAs generates further molecular diversity. There is a need in the art for identifying the different splice forms of the calcium channel subunits, so that they can be used as targets in drug discovery and development programs.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide an isolated and purified α_{1G} subunit of human brain T calcium channel.

It is an object of the present invention to provide an isolated and purified nucleic acid encoding the α_{1G} subunit.

It is an object of the present invention to provide an isolated and purified α_{1I} subunit of human brain T calcium channel.

It is an object of the present invention to provide an isolated and purified nucleic acid encoding the α_{1I} subunit.

It is another object of the present invention to provide an isolated and purified nucleic acid comprising an exon of a human brain T calcium channel alpha subunit.

Another object of the invention is to provide an isolated and purified polypeptide which comprises a translated exon of a human brain T calcium channel.

1

The gene encoding the subunit α_{1X} , where X is A - I, or S, is denoted *CACNA1X*. Alternative names for the SCDF and GHI subfamilies are L and T, respectively.

Another object of the invention is to provide expression vectors and host cells for expressing the subunits of human brain T calcium channel.

Another object of the invention is to provide a method to identify candidate drugs for treating epilepsy.

5 These and other objects of the invention are achieved by one or more of the embodiments described below. In one embodiment an isolated and purified α_{1G} subunit of human brain T calcium channel is provided. The subunit is selected from splice variants 1-64 as shown in Table 1.

10 According to another object of the invention an isolated and purified nucleic acid encoding the α_{1G} subunit is provided.

 According to still another object of the invention an isolated and purified polypeptide is provided which comprises a translated exon selected from the group consisting of 1-38D as shown in Table 2.

15 Another embodiment of the invention is an isolated and purified nucleic acid which comprises an exon selected from the group consisting of 1-38D as shown in Table 2.

 Still another embodiment of the invention is an isolated and purified α_{1I} subunit of human brain T calcium channel selected from splice variants 1-8 as shown in Table 3.

20 The present invention also provides an isolated and purified polypeptide which comprises a translated exon selected from the group consisting of 1-37 as shown in Table 4.

 According to another aspect of the invention an isolated and purified nucleic acid is provided which comprises an exon selected from the group consisting of 1-37 as shown in Table 4.

25 Vectors and host cells which contain and/or express any of the nucleic acids, polypeptides or proteins described above are also contemplated as part of the present invention.

30 Other embodiments of the invention are methods to identify candidate drugs for treating epilepsy. A host cell containing a nucleic acid encoding an α_{1G} or α_{1I} subunit or exon is contacted with a test substance. Uptake by the cell of calcium ions is measured. A test substance which inhibits the uptake by the cell of calcium ions is identified as a candidate drug for treating epilepsy.

These and other embodiments of the invention which will be described in more detail below, and which will be evident to those of ordinary skill in the art upon reading the disclosure, provide the art with new drug discovery targets which can form the basis of a drug screening program.

5 **BRIEF DESCRIPTION OF THE DRAWINGS**

Fig. 1. Map of *CACNA11* and α_{11} cDNA. In the genomic map (bottom), exons are indicated by vertical bars and introns by the connecting horizontal line. The smallest exons are not to scale due to the minimum line thickness required for printing. In the cDNA map (middle), constitutively-spliced, odd-numbered exons are black and even-numbered exons, gray. Alternatively-processed exons (or portions of exons) are colored as follows: 9 – red, 33A – orange, 36B – green. The thinner portions of exons 1 and 36 represent the 5' and 3' untranslated regions, respectively. Selected exons are labeled to facilitate counting. Black bars above this cDNA map indicate relative PCR product locations. Four of the bars are interrupted by a thin line to indicate portions deleted by alternative splicing. Exon 37 (blue) is mutually exclusive with exon 36, requiring a separate representation of the 3' end of the cDNA, at the top. Only a small portion of the exon 37 3' UTR has been amplified and sequenced. Two of the PCR products containing portions of exon 37 are represented as black bars above the partial cDNA map. The starred scale bar equals 1 kb for PCR products and the cDNA maps and 15 kb for the genomic map.

Fig. 2. Schematic of the predicted α_{11} protein. Each aa residue is represented by a small circle. In the large cytoplasmic and extracellular loops, a full up-down cycle measures 100 residues. Main features of the topology are labeled in large type and described in the text. Portions of the protein derived from odd-numbered exons are labeled in small type. A similarity score was computed for each residue from alignments of the aa sequence of each α_{11} exon with the sequences of the homologous human α_{1G} and α_{1H} exons by iterative pairwise use of *gap* with default parameters. *Pipe*, *colon*, *period* and *space* similarity symbols were assigned numerical values of 3, 2, 1 and 0, respectively; α_{11} vs. α_{1G} and α_{11} vs. α_{1H} scores for an individual α_{11} residue were added to yield a final score of 0 to 6. Residue identity in all three proteins produced a score of 6; pairing of an α_{11} residue with unrelated amino acids in both alignments produced

a score of 0. Exons 9, 34 and 35 had no apparent α_{1G} or α_{1H} homologues; these residues are uncolored. Exon 16 had only an α_{1H} homologue and exons 33 and 37 had only α_{1G} homologues; the maximum possible similarity score for these exons is 3. Portions of the protein deleted by alternative splicing have a light blue background. Mutually exclusive exons 36B (7 aa) and 37 (214 aa) are side-by-side. Extracellular cysteines, potential N-glycosylation and phosphorylation sites and the location of splice sites (mapped to the protein product) are indicated by the appropriate symbols. Symbol colors have the following meanings: black – conserved among all human α_1 subunits; purple – conserved within 3 aa residues in the multiple sequence alignment of all human α_1 subunits; blue – conserved among the human ABE and GHI subfamilies; green – conserved among all human T α_1 subunits; brown – also present in human α_{1H} ; orange – also present in human α_{1G} ; pink – unique to α_{1I} . PKA: cyclic-nucleotide-dependent protein kinase phosphorylation site, PKC: protein kinase C phosphorylation site, CKII: casein kinase II phosphorylation site, Tyr: tyrosine kinase phosphorylation site. One residue in the C-terminus was identified as a potential site for phosphorylation by both PKA and CKII; another was identified as a potential site for phosphorylation by both PKA and PKC.

Fig. 3. Map of *CACNA1G* and the α_{1G} cDNA. In the genomic map (bottom), exons are indicated by vertical bars and introns by the connecting horizontal line. The smallest exons are not to scale due to the minimum line thickness required for printing. In the cDNA map (middle), constitutively-spliced, odd-numbered exons are gray and even-numbered exons, black. Alternatively-processed exons (or portions of exons) are colored as follows: 14 – olive, 25B – red, 26 – blue, 34 – light green, 35 – orange, 38B – dark green, 38D – purple. The thinner portions of exons 1 and 38 represent the 5' and 3' untranslated regions, respectively. Selected exons are labeled to facilitate counting. Black bars at the top of the figure indicate PCR product locations relative to the cDNA map. Nine of the bars are interrupted by a thin line to indicate portions deleted by alternative splicing. Red bars (labeled with GenBank accession numbers) represent infant brain cDNA clone ESTs. For one clone, only a 3' EST has been reported. Thin lines indicate portions deleted by alternative splicing

and dashed lines indicate unsequenced portions. The starred scale bar equals 1 kb for PCR products and the cDNA map and 10 kb for the genomic map.

Fig. 4. Schematic of predicted α_{1G} proteins. Each aa residues is represented by a small circle. In the large cytoplasmic and extracellular loops, a full up-down cycle measures 100 residues. Main features of the topology are labeled in large type and described in the text. Portions of the protein involved in alternative splicing have a blue background. These and portions derived from odd-numbered exons are labeled in small type. A similarity score was computed for each residue from alignments of the aa sequence of each α_{1G} exon with the sequences of the homologous human α_{1H} (unpublished observations) and α_{1I} (submitted) exons by iterative pairwise use of gap (Genetics Computer Group, Wisconsin Package Version 9.0) with default parameters. *Pipe*, *colon*, *period* and *space* similarity symbols were assigned numerical values of 3, 2, 1 and 0, respectively; α_{1G} vs. α_{1H} and α_{1G} vs. α_{1I} scores for an individual α_{1G} residue were added to yield a final score of 0 to 6. Residue identity in all three proteins produced a score of 6; pairing of an α_{1G} residue with unrelated amino acids in both alignments produced a score of 0. Exons 14, 16, 26, 35 and 38 had no apparent α_{1H} or α_{1I} homologues; these residues are uncolored. Exon 36 and the C-terminal half of exon 8 had only α_{1H} homologues and exon 34 had only an α_{1I} homologue; the maximum possible similarity score for these regions is 3. Splice sites, extracellular cysteines and potential *N*-glycosylation and phosphorylation sites identified with PROSITE are indicated by the appropriate symbols. Symbol colors have the following meanings: black – conserved among all human α_1 subunits, purple – conserved within 3 aa residues in the multiple sequence alignment of all human α_1 subunits, blue – conserved among the human ABE and GHI subfamilies, green – conserved among all human T α_1 subunits, brown – also present in human α_{1B} , orange – also present in human α_{1H} , pink – unique to α_{1G} . PKA: cyclic-nucleotide-dependent protein kinase phosphorylation site, PKC: protein kinase C phosphorylation site, CKII: casein kinase II phosphorylation site, Tyr: tyrosine kinase phosphorylation site. One residue in ID1-2 was identified as a potential site for phosphorylation by both PKA and PKC.

Fig. 5 is a schematic diagram of the RNA processing leading to the 8 α_{1I} variants.

DETAILED DESCRIPTION OF THE INVENTION

The human brain T calcium channel α_{1G} subunit gene, *CACNA1G*, has now been discovered to consist of 38 protein-coding exons. Alternative processing of the gene transcript allows this single gene to code for sixty-four distinct α_{1G} protein products. In Table 2, each exon or portion of an exon is listed. In Table 1, the component exons of individual splice variants are described. These two tables are sufficient for a complete description of the newly discovered compositions.

Table 1 lists the component exons of the 64 α_{1G} protein products. Only the missing portions of each variant are noted in the description; the symbol “ Δ ” denotes deletion of the exon following the symbol. Thus, variant 1 consists of all exons save 14, 25B, 26, 34, 35 and 38B; in other words, exons 1 – 13, 15- 24, 25A, 27 – 33, 36 – 37, 38A and 38C are concatenated to form the protein. The final column lists the number of aa residues in each variant.

Table 1. α_{1G} Splice Variants

Variant	Description	Exon 14	Exon 25B	Exon 26	Exon 34	Exon 35	Exon 38B	Length (aa)
1	$\Delta 14\Delta 25B\Delta 26\Delta 34\Delta 35\Delta 38B$	—	—	—	—	—	—	2164
2	$\Delta 14\Delta 25B\Delta 26\Delta 34\Delta 35$	—	—	—	—	—	+	2243
3	$\Delta 14\Delta 25B\Delta 26\Delta 34\Delta 38B$	—	—	—	—	+	—	2209
4	$\Delta 14\Delta 25B\Delta 26\Delta 34$	—	—	—	—	+	+	2288
5	$\Delta 14\Delta 25B\Delta 26\Delta 35\Delta 38B$	—	—	—	+	—	—	2212
6	$\Delta 14\Delta 25B\Delta 26\Delta 35$	—	—	—	+	—	+	2291
7	$\Delta 14\Delta 25B\Delta 26\Delta 38B$	—	—	—	+	+	—	2257
8	$\Delta 14\Delta 25B\Delta 26$	—	—	—	+	+	+	2336

9	$\Delta 14\Delta 25B\Delta 34\Delta 35\Delta 38B$	—	—	+	—	—	—	2182
10	$\Delta 14\Delta 25B\Delta 34\Delta 35$	—	—	+	—	—	+	2261
11	$\Delta 14\Delta 25B\Delta 34\Delta 38B$	—	—	+	—	+	—	2227
12	$\Delta 14\Delta 25B\Delta 34$	—	—	+	—	+	+	2306
13	$\Delta 14\Delta 25B\Delta 35\Delta 38B$	—	—	+	+	—	—	2230
14	$\Delta 14\Delta 25B\Delta 35$	—	—	+	+	—	+	2309
15	$\Delta 14\Delta 25B\Delta 38B$	—	—	+	+	+	—	2275
16	$\Delta 14\Delta 25B$	—	—	+	+	+	+	2354
17	$\Delta 14\Delta 26\Delta 34\Delta 35\Delta 38B$	—	+	—	—	—	—	2171

18	$\Delta 14\Delta 26\Delta 34\Delta 35$	—	+	—	—	—	—	+	2250
19	$\Delta 14\Delta 26\Delta 34\Delta 38B$	—	+	—	—	—	+	—	2216
20	$\Delta 14\Delta 26\Delta 34$	—	+	—	—	—	+	+	2295
21	$\Delta 14\Delta 26\Delta 35\Delta 38B$	—	+	—	—	+	—	—	2219
22	$\Delta 14\Delta 26\Delta 35$	—	+	—	—	+	—	+	2298
23	$\Delta 14\Delta 26\Delta 38B$	—	+	—	—	+	+	—	2264
24	$\Delta 14\Delta 26$	—	+	—	—	+	+	+	2343
25	$\Delta 14\Delta 34\Delta 35\Delta 38B$	—	+	+	—	—	—	—	2189
26	$\Delta 14\Delta 34\Delta 35$	—	+	+	—	—	—	+	2268

27	$\Delta 14\Delta 34\Delta 38B$	—	+	+	—	+	+	—	+	2234
28	$\Delta 14\Delta 34$	—	+	+	—	+	+	—	+	2313
29	$\Delta 14\Delta 35\Delta 38B$	—	+	+	+	+	+	—	—	2237
30	$\Delta 14\Delta 35$	—	+	+	+	+	+	+	+	2316
31	$\Delta 14\Delta 38B$	—	+	+	+	+	+	—	—	2282
32	$\Delta 14$	—	+	+	+	+	+	+	+	2361
33	$\Delta 25B\Delta 26\Delta 34\Delta 35\Delta 38B$	+	—	—	—	—	—	—	—	2187
34	$\Delta 25B\Delta 26\Delta 34\Delta 35$	+	—	—	—	—	—	—	+	2266
35	$\Delta 25B\Delta 26\Delta 34\Delta 38B$	+	—	—	—	—	—	+	—	2232

36	$\Delta 25B\Delta 26\Delta 34$	+	—	—	—	+	—	+	+	2311
37	$\Delta 25B\Delta 26\Delta 35\Delta 38B$	+	—	—	+	+	—	—	—	2235
38	$\Delta 25B\Delta 26\Delta 35$	+	—	—	+	+	—	—	+	2314
39	$\Delta 25B\Delta 26\Delta 38B$	+	—	—	+	+	—	+	—	2280
40	$\Delta 25B\Delta 26$	+	—	—	+	+	—	+	+	2359
41	$\Delta 25B\Delta 34\Delta 35\Delta 38B$	+	—	+	—	+	—	—	—	2205
42	$\Delta 25B\Delta 34\Delta 35$	+	—	+	—	+	—	—	+	2284
43	$\Delta 25B\Delta 34\Delta 38B$	+	—	+	—	+	—	+	—	2250
44	$\Delta 25B\Delta 34$	+	—	+	—	+	—	+	+	2329

45	$\Delta 25B\Delta 35\Delta 38B$	+	—	+	+	+	—	—	2253
46	$\Delta 25B\Delta 35$	+	—	+	+	+	—	+	2332
47	$\Delta 25B\Delta 38B$	+	—	+	+	+	+	—	2298
48	$\Delta 25B$	+	—	+	+	+	+	+	2377
49	$\Delta 26\Delta 34\Delta 35\Delta 38B$	+	+	—	—	—	—	—	2194
50	$\Delta 26\Delta 34\Delta 35$	+	+	—	—	—	—	+	2273
51	$\Delta 26\Delta 34\Delta 38B$	+	+	—	—	—	+	—	2239
52	$\Delta 26\Delta 34$	+	+	—	—	—	+	+	2318
53	$\Delta 26\Delta 35\Delta 38B$	+	+	—	—	+	—	—	2242

54	$\Delta 26\Delta 35$	+	+	—	+	—	+	—	+	2321
55	$\Delta 26\Delta 38B$	+	+	—	+	—	+	+	—	2287
56	$\Delta 26$	+	+	—	+	—	+	+	+	2366
57	$\Delta 34\Delta 35\Delta 38B$	+	+	+	+	—	—	—	—	2212
58	$\Delta 34\Delta 35$	+	+	+	+	—	—	—	+	2291
59	$\Delta 34\Delta 38B$	+	+	+	+	—	—	+	—	2257
60	$\Delta 34$	+	+	+	+	—	—	+	+	2336
61	$\Delta 35\Delta 38B$	+	+	+	+	+	+	—	—	2260
62	$\Delta 35$	+	+	+	+	+	+	—	+	2339

63	$\Delta 38B$	+	+	+	+	+	—	2305
64	full	+	+	+	+	+	+	2384

For each exon, the nucleotide sequence and the corresponding amino-acid (aa) sequence are listed in single-letter IUPAC code. Lower case letters in the aa sequences indicate that only two nucleotides of the codon belong to the exon (the codon is interrupted). A dash indicates a stop codon.

Table 2.

(SEQ ID NOs: 1 and 82) Exon 1 (constitutive)

atggacgaggaggagatggagcgggcgccgaggagtcgggacagccccggagcttcatgcggctcaa
cgacctgtcgggggccggggccggccggggccgggtcagcagaaaaggaccgggcagcgcggact
ccgaggcggaggggctgccgtaccggcgctggccccgggtggttttcttctacttgagccaggacagc
cgcccgcggagctggtgtctccgcacggtctgtaaccc

MDEEEDGAGAEESGQPRSFMRNLDSGAGGRPGPSAEKDPGSADSEAEGLPYPALAPVVFYLSQDS
RPRSWCLRTVCNp

(SEQ ID NOs: 2 and 83) Exon 2 (constitutive)

ctggtttgagcgcacatcagcatgttggtcatcttctcaactgcgtgacctgggcatgttccggccat
gcgaggacatcgctgtgactcccagcgtgccggatcctgcag

WFERISMLVILLNCVTLGMFRPCEDIACDSQRCRILQ

(SEQ ID NOs: 3 and 84) Exon 3 (constitutive)

gcctttgatgacttcatctttgccttctttgcctggagatggtggtgaagatggtggccttgggcat
ctttgggaaaaagtgttacctgggagacacttgaaccggcttgactttttcatcgctcatcgagg

AFDDFIFAFFAVEMVVKMVALGIFGKKCYLGDWNRDLFFIVIAg

(SEQ ID NOs: 4 and 85) Exon 4 (constitutive)

gatgctggagtactcgctggacctgcagaacgtcagcttctcagctgtcaggacagtcctgtgtctgc
gaccgctcagggccattaaccgggtgccca

MLEYSLDLQNVSFSAVRTVRVLRPLRAINRVP

(SEQ ID NOs: 5 and 86) Exon 5 (constitutive)

gcatgcgcaccttgtcacgttgcgtgctggatacgctgcccatgctgggcaacgtcctgctgctctgc
ttcttcgtcttcttcatcttcggcatcgctcggcgtccagctgtgggcagggtgcttcggaaccgatg
cttcctacctgagaatttcagcct

SMRILVTLLLDLTPMLGNVLLLCFFVFFIFGIVGVQLWAGLLNRNRCFLPENFS1

(SEQ ID NOs: 6 and 87) Exon 6 (constitutive)

ccccctgagcgtggacctggagcgtattaccagacagagaacgaggatgagagcccccttcatctgct
cccagccacgcgagaacggcatgcggtcctgcagaagcgtgccacgctgcgcggggacggggcggt
ggccaccttgcggtctggactatgaggcctacaacagctccagcaacaccacctgtgtcaactggaa
ccagtactacaccaactgctcagcgggggagcacaaccccttcaaggcgccatcaactttgacaaca
ttggctatgcctggatgccatcttccag

PLSVDLERYQ TENEDSPFICSQPRENGMRSCRSVPTLRGDGGGPPCGLDYEAYNSSNTTCVNNW
QYYTNC SAGEHNPFKGAINFDNIGYAWIAIFQ

(SEQ ID NOs: 7 and 88) Exon 7 (constitutive)

gtcatcacgctggagggtgggtcgacatcatgtactttgtgatggatgctcattccttctacaattt
catctacttcatcctcctcatcatc

VITLEGWVDIMYFVMDAHSFYNFIIYFILLII

(SEQ ID NOs: 8 and 89) Exon 8 (constitutive)

gtgggctccttcttcatgatcaacctgtgcctgggtgattgccacgcagttctcagagaccaagca
gcgggaaagccagctgatgcgggagcagcgtgtgcggttctgtccaacgccagcaccctggctagct
tctctgagcccgccagctgctatgaggagctgctcaagtacctgggtgtacatccttcgtaaggcagcc
cgcagggtggctcaggtctctcgggcagcaggtgtgcgggttgggctgctcagcagcccagcaccct
cgggggccaggagaccagcccagcagcagctgctctcgctcccaccgccgcctatccgtccaccacc
tggtgcaccaccaccaccaccatcaccaccactaccacctgggcaatgggacgctcagggcccccccg
gccagcccgagatccaggacaggatgccaatgggtcccgcaggctcatgctgccaccaccctcgac
gctgcccctctccggggccccccctggtggcgagagctctgtgcacagcttctaccatgccgactgcc
acttagagccagtcctgctgccaggcgccccctcccaggctcccatctgaggcatccggcaggactgtg
ggcagcgggaaggtgtatcccaccgtgcacaccagccctccaccggagacgctgaaggagaaggcact
agtagaggtggctgccagctctgggcccccaacctcaccagcctcaacatcccaccgggccctaca
gctccatgcacaagctgctggagacacagagtacag

VGSFFMINLCLVVIATQFSETKQRESQLMREQRVFLSNASTLASFSEPGSCYEELLKYLVIYLRKAA
RRLAQVSRAAGVRVGLLSSPAPLGGQETQPSSSCSRSHRRLSVHHLVHHHHHHHHHYHLGNGTLRAPR
ASPEIQDRDANGSRRLMLPPPSTPALSGAPPGGAESVHSFYHADCHLEPVRQCAPPSPSEASGRV
GSGKVYPTVHTSPPELKEKALVEVAASSGPPTLSLNIPPGPYSSMHKLELQST

(SEQ ID NOs: 9 and 90) Exon 9 (constitutive)

gtgcctgccaaagctcttgcaagatctccagcccttgcttgaaagcagacagtgaggcctgtggtcca
gacagctgcccctactgtgcccggggcggggcagggggaggtggagctcgccgaccgtgaaatgcctga
ctcagacagcgaggcagtttatgagttcacacaggatgccagcacagcgacctccgggacccccaca

gccggcggaacggagcctgggccagatgcagagcccagctctgtgctggccttctggaggctaatac
tgtgacaccttccgaaagattgtggacagcaagtactttggccgggaatcatgatcgccatcctggt
caacacactcagcatgggcatcgaataccacgagcag

gACQSSCKISSPCLKADSGACGPDSCPYCARAGAGEVELADREMPDSDSEAVYEFTQDAQHSDLRDPH
SRRQRS LGPDAEPSSVLAFWRLICDTFRKIVDSKYFGRGIMIAILVNTLSMGIEYHEQ

(SEQ ID NOs: 10 and 91) Exon 10 (constitutive)

cccaggagccttaccacgcctagaaatcagcaacatcgctcttcaccagcctctttgccctggagat
gctgctgaagctgcttgtgtatggtccctttggctacatcaagaatccctacaacatcttcgatgggtg
tcattgtgggtcatcag

PEELTNALEISNIVFTSLFALEMLLKL LVYGPFGYIKNPYNIFDGVIVVIs

(SEQ ID NOs: 11 and 92) Exon 11 (constitutive)

cggtgtgggagatcggtggccagcagggggcgccgtgctgggtgctgcggaccttccgcctgatgcgtg
tgctgaagctggtgcgttctctgccggcgctgcagcggcagctgggtggtgctcatgaagaccatggac
aacgtggccaccttctgcagtgctgcttatgctcttcacatcttcacatcttcag

VWEIVGQQGGGLSVLRTRFLMRVLKLVRF PALQRQLVVLMTMDNVATFCMLLM LFIFIFs

(SEQ ID NOs: 12 and 93) Exon 12 (constitutive)

catcctgggcagcatctcttcggctgcaagtttgccctctgagcgggatggggacaccctgccagacc
ggaagaattttgactccttgctctgggccatcgctcactgtctttcag

ILGMHLFGCKFASERDGTLPDRKNFDSLLWAI VTVFQ

(SEQ ID NOs: 13 and 94) Exon 13 (constitutive)

atcctgaccaggaggactggaacaaagtcctctacaatggtatggcctccacgtcgctcctgggcggc
cctttatttcattgcctcatgaccttcggcaactacgtgctcttcaatttgctgggtcgccattctgg
tggagggtccaggcgag

ILTQEDWNKVLYNGMASTSSWAALYFIALMTFGNYVLFNLLVAILVEGFQAE

(SEQ ID NOs: 14 and 95) Exon 14 (variable)

gaaatcagcaaacgggaagatgcgagtggacagttaagctgtattcagctgcctgtcgactcccaggg
g

EISKREDASGQLSCIQLPVDSQG

(SEQ ID NOs: 15 and 96) Exon 15 (constitutive)

ggagatgccaacaagtccgaatcagagcccgatttcttctcaccagcctggatggtgatggggacag
gaagaagtgcttggcct

GDANKSESEPDFFSPSLDGDGDRKKCLA

(SEQ ID NOs: 16 and 97) Exon 16 (constitutive)

tgggtgtccctgggagagcaccggagctgcggaagagcctgctgcgcctctcatcatccacacggcc
gccacacccatgtcgctgcccaagagcaccagcagggcctgggagggcgctgggccctgcgtcgcg
ccgcaccagcagcagcgggtcggcagagcctggggcgccacagagatgaagtcaccg

1VSLGEHPELRKSLLPPLIIHTAATPMSLPKSTSTGLGEALGPASRRTSSSGSAEPGAAHEMKSP

(SEQ ID NOs: 17 and 98) Exon 17 (constitutive)

cccagcggccgcagctctccgcacagccctggagcgtgcaagcagctggaccagcaggcgctccag
ccggaacagcctcgccgtgcaccagcctgaagcggagaagcccaagtggagagcggcggtccctgt
tgtcgggagaaggccaggagagccaggatgaagaggagagctcagaagaggagcggggccagccctgcg
ggcagtgacctcgccacaggggtccctggagcgggaggccaagagttcctttgacctgccagacac
actgcaggtgccagggtgcacgcactgccagtggccgagggtctgcttctgagcaccaggactgca
atggcaagtcggttcagggcgcctggccggggccctgcggcctgatgacccccactggatggggat
gacgccgatgacgagggaacctg

PSARSSPHSPWSAASSWTSRRSSRNSLGRAPSLKRRSPSGERRSLLSGEGQESQDEEESSEERASPA
GSDHRHRGSLERAKSSFDLPDTLQVPLHRTASGRGSASEHQDCNGKSASGRALARLRPDDPPLDGD
DADDEGNL

(SEQ ID NOs: 18 and 99) Exon 18 (constitutive)

agcaaaggggaacgggtccgcgctggatccgagcccgactccctgcctgctgcctcgagcgagactc
ctggtcagcctacatcttccctcctcagtccag

SKGERVRAWIRARLPACCLERDSWSAYIFPPQSR

(SEQ ID NOs: 19 and 100) Exon 19 (constitutive)

gttcgcctcctgtgtcaccggatcatcaccacaagatgttogaccacgtggtccttgtcatcatct
tccttaactgcatcaccatcgccatggagcgccccaaaattgacccccacagcgt

FRLLCHRIITHKMFHDHVLVIIFLNCITIAMERPKIDPHSA

(SEQ ID NOs: 20 and 101) Exon 20 (constitutive)

gaacgcacatcttctgacctctccaattacatcttcaccgcagtcttcttggtgaaatgacagtgaag
g

ERIFLTLSNYIFTAVFLAEMTVK

(SEQ ID NOs: 21 and 102) Exon 21 (constitutive)

gtggtggcactgggctggtgcttcggggagcaggcgctacctgcggagcagttggaacgtgctggacgg
gctgttggtgctcatctccgtcatcgacattctggtgtccatggtctctgacagcggcaccaagatcc
tgggcatgctgaggggtgctgcggtgctgcggaccctgcgccgctcag

VVALGWCFFGEQAYLRSSWNVLDGLLVLSVIDILVSMVSDSGTKILGMLRVLRLLRTRLRPLr

(SEQ ID NOs: 22 and 103) Exon 22 (constitutive)

ggtgatcagccgggagcaggggctgaagctggtggtggagacgctgatgtcctcactgaaacccatcg
gcaacattgtagtcatctgctgtgccttcttcatcattttcggcatcttgggggtgcag

VISRAQGLKLVVETLMSSLKPIGNIVVICCAFFIIFGILGVQ

(SEQ ID NOs: 23 and 104) Exon 23 (constitutive)

ctcttcaaagggaagtttttcgtgtgccaggcgaggataccaggaacatcaccaataaatcgactg
tgccgaggccagttaccggtgggtccggcacaagtacaactttgacaaccttgccag

LFKGFVCQGEDTRNITNKSDCAEASYRWVRHKYNFDNLGQ

(SEQ ID NOs: 24 and 105) Exon 24 (constitutive)

gccctgatgtccctgttcgttttggcctccaaggatggttggtggacatcatgtacgatgggctgga
tgctgtgggcgtggaccagcag

ALMSLFLVASKDGWVDIMYDGLDAVGVDQQ

(SEQ ID NOs: 25 and 106) Exon 25A (constitutive)

cccatcatgaaccacaaccctggatgctgctgtacttcacatctcgttcctgctcattgtggccttctt
tgtcctgaacatgtttgtgggtgtggtggtggagaactccacaagtgtcggcagcaccaggaggaag
aggaggcccgcgcgaggaggagaagcgctacgaagactggagaaaaagagaagga

PIMNHNPMWLLYFISFLLIVAFFVLNMFVGVVVENFHKCRQHQEEEEARRREEKRLRRLEKKRR

(SEQ ID NOs: 26 and 107) Exon 25B (variable)

gtaaggagaagcagatggctg

SEKEQMA

(SEQ ID NOs: 27 and 108 and 162) Exon 26 (variable)

atctaagtctggacgatgtaattgcttccggcagctcagccagcgtgcgtcag

nLMLDDVIASGSSASAAS (when follows exon 25A)

dLMLDDVIASGSSASAAS (when follows exon 25B)

(SEQ ID NOs: 28 and 109 and 163) Exon 27 (constitutive)

aagcccagtgcaaaccttactactccgactactcccgttccggctcctcgtccaccacttggtgcacc
agccactacctggacctcttcatcacaggtgtcatcgggctgaacgtggtcaccatggccatggagca
ctaccagcagccccag

eAQCKPYYSYSRFRLLVHHLCTSHYLDLFIITGVIGLNVVTMAMEHYQQPQ (when it follows
exon 25B or exon 26)

kAQCKPYYSYSRFRLLVHHLCTSHYLDLFIITGVIGLNVVTMAMEHYQQPQ (when it follows
exon 25A)

(SEQ ID NOs: 29 and 110) Exon 28 (constitutive)

attctggatgaggctctgaagatctgcaactacatcttcaactgtcatctttgtcttgagtcagttt
caaacttggtggcctttgggttccgtcgggtcttccaggacag

ILDEALKICNYIFTVIFVLESVFKLVAFGFRFFQDr

(SEQ ID NOs: 30 and 111) Exon 29 (constitutive)

gtggaaccagctggacctggccattgtgtgtgtccatcatgggcatcacgctggaggaaatcgagg
tcaacgcctcgctgcccatcaacccccaccatcatccgcatcatgagggtgctgcgcattgcccag

WNQLDLAIVLLSIMGITLEEIEVNASLPINPTIIRIMRVLRIAR

(SEQ ID NOs: 31 and 112) Exon 30 (constitutive)

tgctgaagctgctgaagatggctgtgggcatgcccgcgctgctggacacggtgatgcaggccctgcc
cag

vLKLLKMAVGMRALDITVMQALPQ

(SEQ ID NOs: 32 and 113) Exon 31 (constitutive)

gtggggaacctgggacttctcttcatgtgtgtgttttcatctttgcagctctgggcgtggagctctt
tgagacctgg

VGNLGLLFMLLFFIFAALGVELFGDL

(SEQ ID NOs: 33 and 114) Exon 32 (constitutive)

agtggtgacgagacacacctgtgaggcctgggcccgtcatgccacctttcggaactttggcatggcc
ttcctaaccctcttccgagttctccacaggtgacaattggaatggcattatgaag

eCDETHPCEGLGRHATFRNFGMAFLTLFRVSTGDNWNGIMK

(SEQ ID NOs: 34 and 115) Exon 33 (constitutive)

gacaccctccgggactgtgaccaggagtccacctgctacaacacggcatctcgcctatctactttgt
gtccttcgtgctgacggcccagttcgtgctagtcaacgtggtgatcgccgtgctgatgaagcacctgg
aggagagcaacaaggaggccaaggaggaggccgagctagaggctgagctggagctggagatgaagacc
ctcagccccagccccactcgccactgggcagcccccttctctggcctggggtcgagggccccgacag
ccccgacagccccaagcctggggctctgcaccagcgggccacgcgagatcagcctcccacttttccc
tgagacacccacg

DTLRDCDQESTCYNTVISPIYFVSFVLTAQFVLNVVIAVLMKHLEESNKEAKEEAELEAELEEMKT
LSPQPHSPLGSPFLWPGVEGPDSPDSPKPGALHPAAHARSASHFSLEHPT

(SEQ ID NOs: 35 and 116) Exon 34 (variable)

gacaggcagctgtttgacaccatatccctgctgatccagggtccctggagtgggagctgaagctgat
ggacgagctggcaggcccagggggccagccctctgccttccttctgccccagcctgggaggtccg
acccacag

DRQLFDTISLLIQGSLEWELKLMDLAGPGGQPSAFPSAPSLGGSDPQ

(SEQ ID NOs: 36 and 117) Exon 35 (variable)

atccctctagctgagatggaggctctgtctctgacgtcagagattgtgtctgaaccgtcctgctctct
agctctgacggatgactctttgcctgatgacatgcacacactcttacttagtgccctggagagcaat

IPLAEMEALSLTSEIVSEPSCSLALTDDSLPDDMHTLLLSALESN

(SEQ ID NOs: 37 and 118) Exon 36 (constitutive)

atgcagccccacccacggagctgccaggaccagacttactgactgtcggaagtctggggtcagccg
aacgcactctctgcccattgacagctacatgtgtcgcatgggagcactgccgagggggccctgggac
acaggggctgggggtccccaagctcagtcag

MQPHPTELPGPDLLTVRKSGVSRTHSLPNDSYMCRHGSTAEGPLGHRGWGLPKAQS

(SEQ ID NOs: 38 and 119) Exon 37 (constitutive)

gtccgtcttgtccgttcactcccagccagcagataccagctacatcctgcagcttcccaaagatgca
cctcatctgctccagccccacagcgccccaaactggggcaccatcccaaaactgccccaccaggacg
ctcccccttggctcagaggccactcaggcgccag

gSVLSVHSQPADTSYILQLPKDAPHLLQPHSAPTWGTIPKLPPPGRSPLAQRPLRRQ

(SEQ ID NOs: 39 and 120) Exon 38A (constitutive)

gcagcaataaggactgactccttgacgttcagggtctgggcagccgggaagacctgctggcagag

AAIRTDSLDVQGLGSREDLLAE

(SEQ ID NOs: 40 and 121) Exon 38B (variable)

gtgagtgggccctccccgccctggccggcctactctttctggggccagtcaagtaccaggcaca
gcagcactcccgagccacagcaagatctccaagcacatgaccccgccagccccttgcccaggcccag
aaccctaactggggcaagggccctccagagaccagaagcagcttagagttggacacggagctgagctgg
atctcaggagacctcctgccccctggcgccag

VSGPSPPLARAYSFWCQSSTQAQQHSRSHSKISKHMTTPAPCPGPEPNWKGPPETRSSLDELDTLSW
ISGDLPPGGQ

(SEQ ID NOs: 41 and 122) Exon 38C (constitutive)

gaggagcccccatccccacgggacctgaagaagtgtacagcgtggaggcccagagctgccagcgccggcctacgtc
tctatattttattaaattaattgaatctagta

EEPPSPRDLKKCYSEVAQSCQRRPTSWLDEQRRHSIAVSCLDSGSQPHLGTDP SNLGGQPLGGPGSRP
KKKLSPPSITIDPPESQGPRTPPSPGICLRRRAPSSDSKDPLASGPPDSMAASPSPKKDVL SLSGLSS
DPADLDP-

(SEQ ID NO: 42) Exon 38D (variable)

tatgcgggatgtacgacattttgtgactgaagagacttgtttccttctacttttatgtgtctcagaat
atttttgaggcgaaggcgtctgtctcttggtatttttaacctaaaataacagtctagttatattccct
cttcttgcaaagcacaagctgggaccgcgagcacattgcagccccaacggtggcccatcttcagcgga
gagcgagaaccattttggaaactgtaatgtaacttattttttcctttaacctcgtcatcttttctgt
aggggaaaaaaaaaagaaaaaagaaaaatgagattttacaagtgaatggaacctttttatatatacat
acatacatatctatctatctatctatatataataaaataaagtaattttcctaaataaaaa

Non-coding

The calcium channel α_{11} subunit gene, *CACNA11*, consists of 37 protein-coding exons. Alternative processing of the gene transcript allows this single gene to code for eight distinct α_{11} protein products. In Table 4, each exon or portion of an exon is listed. In Table 3, the component exons of individual splice variants is described. These two tables are sufficient for a complete description of composition. The presumed RNA processing mechanisms giving rise to these variants are discussed below.

5 Table 3 lists the composition of the 8 α_{II} protein products. Only the missing portions of each variant are noted in the description; the symbol " Δ " denotes deletion of the exon following the symbol. Thus, variant 1 consists of all exons save 9, 33A and 36B; in other words, exons 1 – 8, 10 – 32, 33B, 34 – 35, 36A and 37 are concatenated to form the protein. The final column lists the number of aa residues in each variant.

Table 3. α_{II} Splice Variants

Variant	Description	Exon 9	Exon 33A	Exon 36B or 37	Length (aa)
1	$\Delta 9\Delta 33A\Delta 36B$	Δ	Δ	37	2175
2	$\Delta 9\Delta 33A\Delta 37$	Δ	Δ	36B	1968
3	$\Delta 9\Delta 36B$	Δ	+	37	2188
4	$\Delta 9\Delta 37$	Δ	+	36B	1981
5	$\Delta 33A\Delta 36B$	+	Δ	37	2210
6	$\Delta 33A\Delta 37$	+	Δ	36B	2003
7	$\Delta 36B$	+	+	37	2223
8	$\Delta 37$	+	+	36B	2016

For each exon, the nucleotide sequence and the corresponding amino-acid (aa) sequence are listed in single-letter IUPAC code. Lower case letters in the aa sequences indicate that only two nucleotides of the codon belong to the exon (the codon is interrupted). A dash indicates a stop codon.

TABLE 4

(SEQ ID NOs: 43 and 123) Exon 1 (constitutive)

atggctgagagcgccctccccgccctcctcatctgcagcagccccagccgctgagccaggagtcaccac
ggagcagcccgaccggagccccccatcctccccgccaggcctggaggagcctctggatggagctg
atcctcatgtccacacccagacctggcgccattgccttcttctgcctgcgacagaccaccagcccc
cggaactggtgcatcaagatggtgtgcaacc

MAESASPPSSSAAAPAAEPGVTTTEQPGPRSPSSPPGLEEPLDGADPHVPHDLAPIAFFCLRQTTS
RNWCIKMVCNp

(SEQ ID NOs: 44 and 124) Exon 2 (constitutive)

gtggtttgaatgtgtcagcatgctggtgatcctgctgaactgcgtgacacttggcatgtaccagccgt
gcgacgacatggactgcctgtccgaccgctgcaagatcctgcag

WFECVSMVLVILLNVCVTLGMYQPCDDMDCLSDRCKILQ

(SEQ ID NOs: 45 and 125) Exon 3 (constitutive)

gtctttgatgacttcattctttatcttctttgccatggagatggtgctcaagatggtggccctggggat
ttttggcaagaagtgtacctcggggacacatggaaccgcctggatttcttcatcgatggcagg

VFDDFIFIFFAMEMVLKMVALGIFGKKCYLGDTWNRLDFFIVMg

(SEQ ID NOs: 46 and 126) Exon 4 (constitutive)

gatggtcgagtactccctggaccttcagaacatcaacctgtcagccatccgcaccgtgcgcgtcctga
ggccctcaaagccatcaaccgcgtgccca

MVEYSLDLQNINLSAIRTVRVLRPLKAINRVP

(SEQ ID NOs: 47 and 127) Exon 5 (constitutive)

gtatgcggatcctggtgaacctgctcctggacacactgccatgctgggaatgtcctgctgctgc
ttctttgtcttcttcatctttggcatcataggtgtgcagctctggcgggcctgctgcgtaaccgctg
cttctctggaggagaacttcacat

sMRILVNLLDTPMLGNVLLCFFVFFIFGIIGVQLWAGLLRNRCFLEENFTi

(SEQ ID NOS: 48 and 128) Exon 6 (constitutive)

acaaggggatgtggccttgccccatactaccagccggaggaggatgatgagatgcccttcactctgct
 ccctgtcgggagacaatgggataatgggctgccatgagatcccccgctcaaggagcagggccgtgag
 tgctgacctgtccaaggacgacgtctacgactttggggcgggcgccaggacctcaatgccagcgacct
 ctgtgtcaactggaaccgttactacaatgtgtgcccgcagggcagcgccaacccccacaagggtgcca
 tcaactttgacaacatcggttatgcttgattgtcatcttccag

QGDVALPPYYQPEEDDEMPFICSLSGDNGIMGCHEIPPLKEQGRECCLSKDDVYDFGAGRQDLNASGL
 CVNWNRYYNVCRGTSANPHKGAINFDNIGYAWIVIFQ

(SEQ ID NOS: 49 and 129) Exon 7 (constitutive)

gtgatcactctggaaggctgggtggagatcatgtactacgtgatggatgctcactccttctacaactt
 catctacttcatcctgcttatcata

VITLEGWVEIMYYVMDAHSFYNFIIYFILLII

(SEQ ID NOS: 50 and 130) Exon 8 (constitutive)

gtgggctccttcttcatgatcaacctgtgcctcggtgtcatagcgacccagttctcgagaccaagca
 acgggagcaccggctgatgctggagcagcgccgagcgtacctgtcctccagcaggtggccagctacg
 ccgagcctggcgactgctacgaggagatcttccagtatgtctgccacatcctgcgcaaggccaagcgc
 cgcgccttgggacctaccaggccctgcagagccggcgccaggccctgggccccgaggccccggcccc
 cgccaaacctgggccccacgccaaggagcccccgactacc

VGSFFMINLCLVVIATQFSETKQREHRLMLEQRQRYLSSSTVASIAEPGDCYEEIFQYVCHILRKAKR
 RALGLYQALQSRRLGPEAPAPAKPGPHAKEPRHY

(SEQ ID NOS: 51 and 131) Exon 9 (variable)

atgggaagactaagggtcagggagatgaaggagacatctcggaagccggcattgccagactttgcat
 gggcctgcctcccctggaaatgatcactcggaagag

hGKTKGQDGRHLGSRHCQTLHGPA SPGNDHSGR

(SEQ ID NOS: 52 and 132 and 164) Exon 10 (constitutive)

agctgtgcccgaacatagccccctggatgagcagccccacacctggtgcagcccatccccgccacg
 ctggcttccgatcccgcagctgcccttgcctgccagcatgaggacggccggcgccctcgggcctggg
 cagcaccgactcgggccaggagggtcgggctccgggagctccgctggtggcgaggacgaggcggtg
 gggacggggcccgagcagcaggagcggagcctcctcagaactggggaaggaggaggaggaggaggag
 caggcggtggtctggctgtgcgggatgtgtggcgggagacgcgagccaagctgcgcggcat
 cgtggacagcaagtacttcaaccggggcatcatgatggccatcctggtcaacaccgtcagcatgggca
 tcgagcaccacgagcag

eLCPQHSPLDATPHTLVQPIPATLASDPASCPCCQHEDGRRPSGLGSTD SGQEGSGSGSSAGGEDEAD
 GDGARSSSEDGASSELGKEEEEEEQADGAVWLCGDVWRETRAKLRGIVDSKYFNRGIMMAILVNTVSMG
 IEHHEQ (when it follows exon 9)

qLCPQHSPLDATPHTLVQPIPATLASDPASCPCCQHEDGRRPSGLGSTD SGQEGSGSGSSAGGEDEAD
 GDGARSSSEDGASSELGKEEEEEEQADGAVWLCGDVWRETRAKLRGIVDSKYFNRGIMMAILVNTVSMG
 IEHHEQ (when it follows exon 8)

(SEQ ID NOs: 53 and 133) Exon 11 (constitutive)

ccggaggagctgaccaacatcctggagatctgcaatgtggtcttcaccagcatgtttgccctggagat
 gatcctgaagctggctgcatttgggctcttcgactacctgcgtaaacccctacaacatcttcgacagca
 tcattgtcatcatcag

PEELTNILEICNVVFTSMFALEMILKLAAPGLFDYLRNPYNIFDSIIIVII_s

(SEQ ID NOs: 54 and 134) Exon 12 (constitutive)

catctgggagatcgtggggcaggcggacggtgggctgtcgtgctgcggaccttcgggctgctgcgcg
 tgctgaaactggtgcgcttcagcctgccctgcggcgccagctcgtggtgctcatgaagaccatggac
 aacgtggccaccttctgcatgctgctcatgctcttcattcttcattcag

IWEIVGQADGGLSVLRTRFLLRVLKLVRFPALRRQLVVLMTMDNVATFCMLLMLFIFIF_s

(SEQ ID NOs: 55 and 135) Exon 13 (constitutive)

catccttgggatgcatatttttggctgcaagttcagcctccgcacggacactggagacacggtgcccg
 acaggaagaacttcgactccctgctgtgggccatcgtcactgtgttcag

ILGMHIFGCKFSLRTDTGDTVPRKNFDSLLWAIIVTVFQ

(SEQ ID NOs: 56 and 136) Exon 14 (constitutive)

atcctcaccaggaggactggaacgtcgttctctacaatggcatggcctccacttctccctgggcctc
 cctctactttgtgcacctcatgacctcggcaactatgtgctcttcaacctgctggtggccatcctgg
 tggagggttccaggcggag

ILTQEDWNVVLNGMASTSPWASLYFVALMTFGNYVLFNLLVAILVEGFQAE

(SEQ ID NOs: 57 and 137) Exon 15 (constitutive)

ggtgacgccaatcgctcctactcggacgaggaccagagctcatccaacatagaagagtttgataagct
 ccaggaaggcctggacagcagcggag

GDANRSYSDQSSSNIEEFDKLQEGLDSSG

(SEQ ID NOs: 58 and 138) Exon 16 (constitutive)

atcccaagctctgcccataccccatgacccccaatgggcacctggacccccagtctcccactgggtggg
 cacctaggtcctgctggggctgcgggacctgcccccgactctcactgcagccggacccccatgctggt
 ggccctgggctcccgaaagagcagtgatgtctcttagggaggatgagctatgaccagcgctccctg
 dPKLCPIPMTPNGHLDPSPPLGGHLGPAGAAGPAPRLSLQDPMLVALGSRKSSVMSLGRMSYDQSL

(SEQ ID NOs: 59 and 139) Exon 17 (constitutive)

tccagctcccggagctcctactacgggcatggggccgcagcgcggcctgggcccagccgtcgctccag
 ctggaacagcctcaagcacaagccgcctgcggcgagcatgagtcctgctctctgcggagcgcggcg
 gggcgccccgggtctgcgaggttgccgcggacgaggggcccgcggcgggccgcacccctgcacacccca
 cagcccaccacattcatcacgggccccatctggcgacccgccaccgccaccaccgcggagcgtgtc
 cctcgacaacagggactcggaggacctggccgagctggtgcccgcggtgggcgccccccccgggccc
 cctggagggcggcaggccccggccccgggcatgaggactgcaatggcaggatgccagcatcgccaaa
 gacgtcttcaccaagatgggcgaccgcggggatcgcggggaggatgaggaggaaatcgactac

SSSRSSYYGPWGRSAAWASRRSSWNSLKHKPPSAEHESLLSAERGGGARVCEVAADEGPPRAAPLHTP
 HAHHIHHGPHLAHRHRHRRRTLSDNRDSVDLAELVPAVGAHPRAAWRAAGPAPGHEDCNGRMPSIAK
 DVFTKMGRDRGRGEDEEEIDY

(SEQ ID NOs: 60 and 140) Exon 18 (constitutive)

accctgtgcttccgcgtccgcaagatgatcgacgtctataagcccgactggtgcgagggtccgcgaaga
 ctggtctgtctacctcttctctcccgagaacag

TLCFRVRKMIDVYKPDWCEVREDWSVYLFSPENr

(SEQ ID NOs: 61 and 141) Exon 19 (constitutive)

gttccgggtcctgtgtcagaccattattgccacaaactcttcgactacgtcgctcctggccttcatct
 ttctcaactgcatcaccatcgccctggagcggcctcagatcgaggccggcagcacc

FRVLCQTIIAHKLFDYVVLAFIFLNCITIALERPQIEAGST

(SEQ ID NOs: 62 and 142) Exon 20 (constitutive)

gaacgcatctttctcaccgtgtccaactacatcttcacggccatcttcgtgggcgagatgacattgaa
 g

ERIFLTVSNYIFTAIFVGEMTLK

(SEQ ID NOs: 63 and 143) Exon 21 (constitutive)

gtagtctcgctgggcctgtacttcggcgagcaggcgtacctacgcagcagctggaacgtgctggatgg
 ctttcttgtcttcgtgtccatcatcgacatcggtggtccctggcctcagccgggggagccaagatct
 tgggggtcctccgagttctgcggctcctgcgcaccctacgccccctgcg

VVSLGLYFGEQAYLRSSWNVLDFLVFVSIIDIVVSLASAGGAKILGVLRLRLRLRPLr

(SEQ ID NOs: 64 and 144) Exon 22 (constitutive)

tgtcatcagccggcgccggcgctgaagctggtggtggagacactcatctcctccctcaagcccatcg
gcaacatcgtgctcatctgctgtgccttcttcatcatctttggcatcctgggagtgcag

VISRAPGLKLVVETLISSLKPIGNIVLICCAFFIIFGILGVQ

(SEQ ID NOs: 65 and 145) Exon 23 (constitutive)

ctcttcaagggcaagttctaccactgtctggcggtggacaccgcaacatcaccaaccgctcggactg
catggccgccaactaccgctgggtccatcacaaatacaacttcgacaacctgggccag

LPKKGKFIYHCLGVDTRNITNRSDCMAANYRWVHHKYNFDNLGQ

(SEQ ID NOs: 66 and 146) Exon 24 (constitutive)

gctctgatgtccctctttgtcctggcatccaaggatggttgggtgaacatcatgtacaatggactgga
tgctgttgctgtggaccagcag

ALMSLFVLASKDGWVNIMYNGLDAVAVDQQ

(SEQ ID NOs: 67 and 147) Exon 25 (constitutive)

cctgtgaccaaccacaaccctggatgctgctgtacttcatctccttccctgctcatcgctcagcttctt
tgtgtccaacatgtttgtgggtgtcgtggtggagaacttcacaagtgccggcagcaccaggaggctg
aagaggcacggcgcgctgaggagaagcggctgcggcgccctggagaagaagcgccgga

PVTNHNPNWMLLYFISFLLIVSFFVLNMFVGVVVENFHKCRQHQAEEARRREEKRLRRLEKKRR

(SEQ ID NOs: 68 and 148) Exon 26 (constitutive)

aggcccagcggtgccctactatgccacctattgtcacaccggctgctcatccactccatgtgcacc
agccactacctggacatcttcatcaccttcatcatctgcctcaacgtggtcaccatgtccctggagca
ctacaatcagcccacg

KAQRLPYATYCHTRLLIHSMTSHYLDIFITFIICLNVTMSLEHYNQPT

(SEQ ID NOs: 69 and 149) Exon 27 (constitutive)

tccttgagacagccctcaagtactgcaactatatgttcaccactgtctttgtgctggaggctgtgct
gaagctggtggcatttggtctgaggcgcttcttcaaggaccg

SLETALKYCNMFTTVFVLEAVLKLVAFGRLRRFFKDr

(SEQ ID NOs: 70 and 150) Exon 28 (constitutive)

atggaaccagctggacctggccattgtgctactgtcagtcacatgggcatcacctggaggagatcgaga
tcaatgcgccctgcccataatcccaccatcatccgcatcatgagggttctgcgcattgcccag

WNQLDLAIVLLSMGITLEEIEINAALPINPTIIRIMRVLRIAR

(SEQ ID NOs: 71 and 151) Exon 29 (constitutive)

tgctgaagctgttgaagatggccacaggaatgcgggccctgctggacacggtggtgcaagctttgcc
cag

vLKLLKMATGMRALLDTVVQALPQ

(SEQ ID NOs: 72 and 152) Exon 30 (constitutive)

gtgggcaacctgggcctcctcttcatgctgctcttcttcatctatgctgctctcggggtggagctctt
tggaagctgg

VGNLGLLFMLFFIYAALGVELFGKL

(SEQ ID NOs: 73 and 153) Exon 31 (constitutive)

tctgcaacgacgagaacctgtgcgagggcatgagccggcatgccaccttcgagaacttcggcatggcc
ttcctcacactcttccaggtctccacgggtgacaactggaacgggatcatgaag

vCNDENPCEGMSRHATFENFGMAFLTLFQVSTGDNWNGIMK

(SEQ ID NOs: 74 and 154) Exon 32 (constitutive)

gacacgctgcgggactgcacccacgacgagcgcagctgcctgagcagcctgcagtttggtgcgcgct
gtacttcgtgagcttcgtgctcacgcgcagttcgtgctcatcaacgtggtggtggctgtgctcatga
agcacctggacgacagcaacaaggaggcgcaggaggacgccgagatggatgccgagctcgagctggag
atggcccatggcctgggccctggcccgaggtgcctaccggctccccggcgccctggccgagggcc
gggagggcgggcgggcgggggcgacaccgagggcggttggtgccggcgctgctactgcgctgccag

DTLRDCTHDERSCLSLQFVSPLYFVSFVLTAQFVLINVVAVLMKHLDDSNKEAQEDAEMDAELELE
MAHGLGPGPRLPTGSPGAPGRGPGGAGGGDTEGGLCRRCYSPAQ

(SEQ ID NOs: 75 and 155) Exon 33A (variable)

gagaacctgtggctggacagcgtctctttaatcatcaag

ENLWLDSVSLIHK

(SEQ ID NOs: 76 and 156) Exon 33B (constitutive)

gactccttgagggggagctgaccatcatcgacaacctgtcgggctccatcttccaccactactctc
gcctgccggctgcaagaagtgtcaccacgacaagcaagag

DSLEGELTIIDNLGSGIFHHYSSPAGCKKCHHDKQE

(SEQ ID NOs: 77 and 157) Exon 34 (constitutive)

gtgcagctggctgagacggaggccttctccctgaactcagacaggtcctcgtccatcctgctgggtga
cgacctgagctctcgaggacccacagcctgccacctggccgcaaagacagcaag

VQLAETEAFLNSDRSSSILLGDDLSLEDPTACPPGRKDSK

(SEQ ID NOs: 78 and 158) Exon 35 (constitutive)

ggtgagctggaccacctgagcccatgcgtgtgggagacctgggcgaatgcttcttccccttgcctc
tacggcgtctcgccgatccagagaacttctgtgtgagatggaggagatccattcaacctgtcc
ggtcctggctgaaacatgacagcagtcgaag

GELDPPEPMRVGDLGECFFPLSSTAVSPDPENFLCEMEEIPFNPVRSWLKHDSSQ

(SEQ ID NOs: 79 and 159) Exon 36A (constitutive)

caccccccaagtccttctccccggatgcctccagccctctcctgcccatgccagccgagttcttccac
cctgcagtgtctgccagccagaaaggccagaaaaggcactggcactggaacctcccccaagattgc
gctgcagggtcctcctgggcatctctcggtcaccaagggtcaactgtaccctcctccggcag

aPPSPFSPDASSPLLMPAEFFHPAVSASQKGPEKGTGTGTLPKIALQGSWASLRSPRVNCTLLRQ

(SEQ ID NOs: 80 and 160) Exon 36B (mutually exclusive with Exon 37)

gtaccgacacctcccaggccctagagcactggtctgtgggcaaggggcaggatctaagccaggcct
ggaagtccaagggactgggaggggaaggaccaaccaaggccgagggcaccaccgtgcaaggggg
tttggaacgctggggtgacgctgagactggaggggaggtggcactgggcggtgagtgaggcg
gggctgggtcctgggacagcagagtggtgggaggacccaaggcgggtctggaagaggcctgtga
tccttagcttgaggggaggggaggagaggaggagtactggaggttttgagggtggcggggtg
ctggcagtgggaggacacctgggtgctctgggtgggtgtgagtgggggcttgattactaggaat
ggaggtgggagggcggtctggtggatgagaagcctcgggctgcagggtccccgactgagattgg
ccagggccacagccctcctaccacgggcacacagaggtctgaagcactgagggctccgctgtggg
ggtggggaaatggggccgggcccggctcccacagtgagtgcagttgattcactgggtgactgtctga
cccgtcacaccaggctgtgtgctctggcgggcaggacacaaactccctgcctgccgggctcactgt
ttagtgtgagagtgagctgcctgggtgcaggagggtgataacaaaaataaa

VPTPPRP-

(SEQ ID NOs: 81 and 161) Exon 37 (mutually exclusive with exon 36B)

gccaccgggagcgacacgtcgctggacgccagccccagcagctccgcgggcagcctgcagaccacgct
cgaggacagcctgacctgagcgacagccccggcgtgccctggggccgcccgcgctgctccaggac
ccccggcggcctgtcccccgccgtcgccggcgcctgagcctgcgcgggcggggcctcttcagcctg
cgggggctgcggggcgcatcagcgagccacagcagcgggggtccaccagccccgggtgcacccacca

cgactccatggagaccctcgagacgaggagggcgcggtggcgcgggcgggggcgcgggcagcgagc
actcggagaccctcagcagcctctcgctcacctccctcttctgcccgcgcggcgcccgccagccccc
ggcctcacgcccgcaggaagttagcagcaccagcagcctggccgccccggcgccccccacgcccgc
cgccctggcccacggcctggcccggagccctcgtagggcgcgggaccgcagcaaggacccccccggcc
gggcaccgctgcccatgggcctggggcccttggcgccccgcgcgaaccgctccccggagagctggag
ccggggagacgcccagcaagaggaagagatgagggctcgagggggcccccgccgcccaccgcccgc
ccgtctcaccttctttacctcaggagccaggagcagacagcaatacttcgtccacacctgggatcgcg
cagggcccgcagggcacaggcgcccgacagccgggctgagcggagtctgggttagccaggcctgctg
gcccattggtggcccttccagtgcatacacatacatatatatatatgcatatatatatatatata
tatatatatgtgtatacacacacacatagacagacatatatatatatattttttttttactgagag
cttatgacttc

ATGSDTSLDASPSSAGSLQTTLEDSTLSDSPRRALGPPAPAPGPRAGLSPAARRRLSLRGRGLFSL
RGLRAHQSRSHSSGGSTSPGCTHHDSMDPSDEEGRGGAGGGGAGSEHSETLSSLSLTSLFCPPPPPPAP
GLTPARKFSSTSSLAAPGRPHAAALAHGLARSPSWAADRSKDFPGRAPLPMGLGPLAPPPQPLPGELE
PGDAASKRKR-

RNA processing mechanisms

Figure 5 is a schematic diagram of the RNA processing leading to the 8 variants. The portion of the Figure above the scale bar represents the *CACNAII* gene. The three sections of the gene involved in alternative processing are drawn to scale.

5 At the left, variable exon 9 (olive) is flanked by constitutive exons 8 (black) and 10 (purple). The black lines between exons represent introns.

In the middle, constitutive exon 32 is black. Exon 33 is divided into 2 parts, 39-nucleotide (nt) variable exon 33A (orange) and 108-nt constitutive exon 33B (blue).

10 At the right, exon 36 is divided into 2 parts, 197-nt constitutive exon 36A (black) and variable exon 36B (red), encoding seven aa before a stop codon. Constitutive exon 37 (green) encodes 214 aa before a stop codon.

Exons 1 – 7, 11 –31 and 34 – 35 are not represented.

15 The blue and red lines and red arrow above and below the exons represent alternative RNA processing reactions.

Below the scale bar are representations of the 8 α_{II} protein products. The portions of the protein derived from exons 1 – 7, 11 – 31 and 34 – 35 are uncolored. Portions derived from the other exons are color-coded as in the gene map, above. Note that exon 36B encodes only 7 aa. The thin blue and red lines above the protein

products correspond to the lines around the gene map and represent the type of RNA processing reactions that resulted in the particular variant.

a. Alternative splicing of exon 9

5 Variants 1 – 4 result from the deletion of exon 9. In the blue reaction, splicing takes place between the donor 3' to exon 8 and the acceptor 5' to exon 10. Variants 5 – 8 result from RNAs subjected to the red reactions. In this case, two splicing reactions take place. The donor 3' of exon 8 and the acceptor 5' of exon 9 are joined as are the donor 3' of exon 9 and the acceptor 5' of exon 10. The portion encoded by exon 9 is retained.

10 b. Selection of the splice acceptor preceding exon 33A or 33B

Variants 1, 2, 5 and 6 result from the deletion of exon 33A. In the blue reaction, splicing takes place between the donor 3' of exon 32 and the acceptor internal to exon 33. Variants 3, 4, 7 and 8 result from RNAs subjected to the red reaction. In this case, splicing takes place between the donor 3' of exon 32 and the acceptor 5' of exon 33. The portion encoded by exon 33A is retained.

15 c. Processing of the 3' end

Variants 1, 3, 5 and 7 result from the deletion of exon 36B. In the blue reaction, splicing takes place between the donor internal to exon 36 and the acceptor 5' of exon 37. Exon 37 encodes the final 214 aa of the protein in these variants. Variants 20 2, 4, 6 and 8 result from RNAs subjected to the red reaction. In this case, the RNA is cleaved and polyadenylated just 3' of exon 36. In these variants, exon 36B encodes the final 7 aa of the protein.

Isolated and purified polypeptides or proteins, according to the present invention comprise at least about 10% by weight of a composition of proteins. Preferably the 25 composition contains at least 25%, 50%, 75%, 85%, or 90% by weight of the particular polypeptide or protein. Any purification method can be applied, either to naturally expressing cells, such as neurons, or to cells which have been engineered to express a recombinant form of the polypeptide or protein. Purification methods known in the art which can be used without limitation include affinity 30 chromatography, immunoprecipitation, immunoaffinity chromatography, molecular sieves, and ion exchange chromatography.

Non-naturally occurring variants which retain substantially the same biological activities as naturally occurring protein variants, such as calcium channel function, are also included here. Preferably, naturally or non-naturally occurring variants have amino acid sequences which are at least 85%, 90%, or 95% identical to the amino acid sequences shown in the SEQUENCE LISTING found at the end of the application. More preferably, the molecules are at least 98% or 99% identical. Percent identity is determined using the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 1. The Smith-Waterman homology search algorithm is taught in Smith and Waterman, *Adv. Appl. Math.* (1981) 2:482-489.

Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity can be found using computer programs well known in the art, such as DNASTAR software. Preferably, amino acid changes in secreted protein variants are conservative amino acid changes, *i.e.*, substitutions of similarly charged or uncharged amino acids. A conservative amino acid change involves substitution of one of a family of amino acids which are related in their side chains. Naturally occurring amino acids are generally divided into four families: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids.

It is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the biological properties of the resulting variant. Whether an amino acid change results in a functional calcium channel subunit protein or polypeptide can readily be determined by testing the altered protein or polypeptide in a functional assay.

Variants of the calcium channel subunit proteins disclosed herein include glycosylated forms, aggregative conjugates with other molecules, and covalent

conjugates with unrelated chemical moieties. Covalent variants can be prepared by linking functionalities to groups which are found in the amino acid chain or at the N- or C-terminal residue, as is known in the art. Variants also include allelic variants, species variants, and muteins. Truncations or deletions of regions, particularly exons, which do not affect functional activity of the proteins are also variants.

A subset of mutants, called muteins, is a group of polypeptides in which neutral amino acids, such as serines, are substituted for cysteine residues which do not participate in disulfide bonds. These mutants may be stable over a broader temperature range than native proteins or have other beneficial changes in physicochemical properties.

Any coding sequence can be used to generate a recombinant form of the protein which results in the proper amino acids being used. However, the natural human nucleic acid sequences are preferred. The coding sequence can be fused, for example, to expression control sequences, signal sequences, and/or to other coding sequences to form a fusion protein. All of the exons of a particular subunit can be used in such constructs. Alternatively one or more isolated exons can be used.

Nucleic acids which are isolated and purified are separated from the rest of the chromosome on which they reside in human cells. Preferably the particular nucleic acid is the predominant molecular species in a composition. More preferably the nucleic acid comprises at least 75%, 80%, 85%, 90%, or 95% of the molecular species (including only nucleic acids) in the composition.

Degenerate polynucleotide sequences which encode amino acid sequences of the proteins and variants, as well as homologous nucleotide sequences which are at least 65%, 75%, 85%, 90%, 95%, 98%, or 99% identical to the nucleotide sequences shown in the Sequence Listing are also polynucleotide molecules of the invention. Percent sequence identity is determined using computer programs which employ the Smith-Waterman algorithm, such as the MPSRCH program (Oxford Molecular), using an affine gap search with the following parameters: a gap open penalty of 12 and a gap extension penalty of 1.

Typically, homologous polynucleotide sequences can be confirmed by hybridization under stringent conditions, as is known in the art. For example, using

the following wash conditions—2 x SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0), 0.1% SDS, room temperature twice, 30 minutes each; then 2 x SSC, 0.1% SDS, 50 °C once, 30 minutes; then 2 x SSC, room temperature twice, 10 minutes each--homologous sequences can be identified which contain at most about 25-30% basepair mismatches. More preferably, homologous nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.

The nucleic acid can be cloned into a vector, particularly an expression vector. Any suitable expression vector as is known in the art may be used without limitation. Host cells are preferably used which are human, although other host cells including yeast, bacteria, insect, plant and mammalian cells can be used. The cells can be selected for their desired properties. Typically these are selected for their interaction with a vector, or for a property which renders nucleic acids or proteins easily obtainable from the cells.

Host cells which express an α_1 subunit according to the present invention or an α_1 polypeptide can be used to test compounds or compositions for their possible beneficial effect for treating epilepsy. Thus, a test substance can be contacted with such a host cell and the calcium ion uptake by the cell can be measured. A test substance which blocks calcium ion uptake by the cell is identified as a candidate drug for treating or preventing epilepsy. Methods for measuring calcium uptake are known in the art, and any such method may be used for drug identification. See for example, Lee *et al.*, *J. Neuroscience* 19:1912-21, 1999.

The following examples are provided to demonstrate how the invention was made. However, the subject matter of the invention is not limited to any particular method of making the claimed polypeptides, proteins, vectors, and host cells.

EXAMPLES

Example 1

Analysis of sequence produced by the Human Chromosome 22 Sequencing Group at the Sanger Centre revealed putative exons of a T α_1 subunit gene in three overlapping clones of a human genomic DNA library mapping to 22q12.3-13.2: dJ1104E15 (AL022312), dJ206C7 (AL008716) and dJ172B20 (AL022319). *tblastn* alignment with the α_1 G (AF027984) or α_1 H (AF051946) amino-acid (aa) sequence

identified 26 exons; **FEX** analysis, another six; and inspection of upstream sequence, a candidate exon encoding the N-terminus. Potential polyadenylation signals were located with **POLYAH**. Putative exons were assembled into a provisional cDNA sequence and primers for polymerase chain reaction (PCR)-amplification of overlapping portions of the cDNA were designed with **OLIGO** (National Biosciences).

PCR screening of a multiple-tissue cDNA panel (Clontech #K14201) revealed brain as the most abundant cDNA source. Hence, human brain cDNA (Clontech #74001) served as template in subsequent PCRs. The predominant (and in some cases secondary) product of each PCR was recovered on a spin-column (Qiagen #28704) after agarose gel electrophoresis, eluted in water and submitted for sequencing. Exon boundaries were determined by comparison of the cDNA and genomic sequences; ambiguity was resolved by matching potential donors and acceptors to consensus sequences.

Fig. 1 shows 28 of the 49 overlapping PCR products (top) that contributed to the cDNA sequence. Also pictured are exon maps of the cDNA (middle) and the gene (bottom). *CACNA11* consists of at least 37 exons distributed over at least 116,390 basepairs (bp). Most PCRs yielded a single product suggesting constitutive splicing of 33 exons (colored gray or black in the cDNA and genomic maps). Certain PCRs, however, yielded multiple products (interrupted black bars), indicative of alternative splicing. PCRs spanning the 105-nucleotide (nt) exon 9 (red), for example, yielded two products, (14 and +14; thus, exon 9 is a cassette exon subject to type A alternative splicing. Sequencing of PCR products spanning exon 33 revealed that exon 33 harbors an internal acceptor that leads to type C alternative splicing and deletion of 39 nt at the 5' end of the exon defined as exon 33A (orange).

Sequence analysis suggested the possibility of alternative 3' exons. Indeed, PCR-amplification of brain cDNA followed by sequencing showed two forms with substantially different 3' termini. In the first form, both exon 36A and 36B (green) are part of the mature mRNA. Exon 37 (blue) is presumably lost as a result of polyadenylation and cleavage at a site 686 bp downstream of the stop codon in exon 36B. In the second form, splicing between an alternative donor internal to exon 36

and the acceptor 5' of exon 37 leads to substitution of exon 36B with exon 37. The polyadenylation signal of exon 37 has not been identified.

Introns 2 – 8 and 11 – 35 are common U2type GTAG introns. The donors of introns 9 and 10 begin with the dinucleotide GC. Intron 1, like its counterparts in *CACNAIG*, *CACNAIH* (unpublished observations), and *CACNAIA*, is a rare U12type ATAC intron. Exon 1 includes at least 709 bp of 5' untranslated region and the putative start codon.

Fig. 2 shows a schematic of the deduced protein product. Sequence alignment with other members of the α_1 subunit family suggests a transmembrane topology with four domains (D1 – D4), each consisting of six membrane-spanning segments, a pore loop and cytoplasmic and extracellular connecting loops. The domains are linked by interdomain loops (ID12, ID23, ID34), which, along with the amino- (N) and carboxyl- (C) termini, reside in the cytoplasm. Six of the 35 α_1 I splice sites (black bars) are conserved in the other α_1 subunits studied to date, α_{1A} , α_{1C} , α_{1D} , α_{1F} , α_{1S} , α_{1G} and α_{1H} and another three are located within nine nucleotides in the multiple sequence alignment (purple bars). Seventeen of the splice sites (green bars) are in identical locations in the other T subunits, but are not conserved in non-T subunits. Only nine splice sites (pink bars) are unique to α_1 I; these sites join exons that contribute to the cytoplasmic ID1-2, ID2-3 and C-terminus. As indicated by residue color-coding, α_{1I} is quite similar to the two other human T α_1 subunits in its membrane-spanning segments — 84% of residues are identical and 92% have similarity scores (4 (see legend). Likewise, the pore loops and ID34 are similar. Apart from islands of similarity, the large extracellular loop of D1, the N- and C-termini and ID12 and ID23 differ from their counterparts in α_{1G} and α_{1H} . Five potential *N*-glycosylation sites in putative extracellular portions of the protein and 28 potential phosphorylation sites in putative cytoplasmic portions were identified with PROSITE. Although some of the potential phosphorylation sites are conserved among the T α_1 subunits, the majority are unique to α_{1I} . Seventeen extracellular cysteines, including six conserved in all ten reported human α_1 subunits (black and

purple hooks) and nine conserved among T α_1 subunits (green hooks), may play a role in maintaining proper conformation of the extracellular portions of the protein.

Regions derived from portions of the RNA subject to alternative processing are highlighted with a blue background. The shortest predicted product
5 ($\Delta 9\Delta 33A\Delta 37$) has 1,968 aa residues; the longest ($\Delta 36B$), 2,223 aa residues. The reported rat orthologue corresponds to the human $\Delta 9\Delta 36B$ variant with a few differences. Exon 32 of the human gene lacks an 18-aa stretch of cysteines, glycines and prolines found in rat (arrow). In addition, 40 nt of exon 34 are deleted in the rat sequence. This leads to a frameshift and early termination of the rat aa sequence. In
10 addition, the published rat sequence contains sequencing errors in exon 35.

T currents display heterogeneity of biophysical and pharmacological properties and subcellular localization. Identification of multiple T α_1 subunit genes reveals one likely source of heterogeneity. Indeed, heterologous expression experiments demonstrate biophysical differences among the isoforms. The molecular diversity
15 generated by alternative splicing of T α_1 subunit genes has the potential to yield additional functional diversity. *CACNAII* is subject to alternative splicing in at least two exons while *CACNAIG* undergoes alternative splicing in at least six (unpublished observations). Variation in channel phosphorylation and isoform-specific interactions with other proteins may also contribute to diversity. Knowledge of the
20 α_{11} aa sequence and its variants will allow explicit tests of these ideas.

EXAMPLE 2

The human chromosome 17 genomic DNA of clone hCIT.22_K_21 (AC004590, Whitehead Institute/MIT Center for Genome Research) appeared to include most or all of *CACNAIG*, a gene encoding the T Ca^{2+} channel α_{1G} subunit.
25 Thirty-four probable exons were identified by **blastn** alignment with the rat α_{1G} cDNA sequence (AF027984). Four potential polyadenylation signals were located by **blastn** alignment with sequences (R40146, R43876, R43935, R46109) derived from the 3' end of infant brain cDNA clones. A provisional cDNA sequence was assembled and primers for polymerase chain reaction (PCR)-amplification of
30 overlapping portions of human brain cDNA (Clontech #74001) were designed with **OLIGO** (National Biosciences).

PCR products were fractionated by agarose-gel electrophoresis. When adequately resolved, individual products were cut from the gel, recovered on a spin-column (Qiagen #28704), eluted in water and submitted for sequencing. When resolution was incomplete, DNA was recovered from the gel for cloning into pCRΔ2.1-TOPO (Invitrogen #K4500-01). Insert DNA was PCR-amplified from overnight cultures of white colonies, purified by agarose-gel electrophoresis and submitted for sequencing. Exon boundaries were determined by comparison of the cDNA and genomic sequences; ambiguity was resolved by matching potential donors and acceptors to consensus sequences. All reported splice variants were observed in at least two independent PCRs.

Fig. 3 shows 25 of the 83 overlapping PCR products (top, black bars) that contributed to the cDNA sequence (AF134985, AF134986). Also pictured are exon maps of the cDNA (middle) and the gene (bottom). *CACNA1G* consists of at least 38 exons distributed over at least 66,490 basepairs (bp). Thirty-four exons have counterparts in the rat cDNA sequence; exons 14, 26, 34 and 35 are newly-identified. Most PCRs yielded a single product suggesting constitutive splicing of 32 exons (colored gray or black in the cDNA and genomic maps). Certain PCRs, however, yielded multiple products (interrupted black bars), indicative of alternative splicing. PCRs spanning the 69-nucleotide (nt) exon 14 (brown), for example, yielded two products, Δ14 and +14; thus, exon 14 is a cassette exon subject to type A alternative splicing. PCRs spanning cassette exons 34 (144 nt) and 35 (135 nt) yielded three products (Δ34Δ35, +34Δ35 and +34+35); the Δ34+35 product was not detected. Sequencing of PCR products spanning exons 25 and 26 revealed that exon 25 harbors an internal donor that leads to type D alternative splicing and deletion of 21 nt at the 3' end of the exon (defined as exon 25B, red); the 54-nt exon 26 (blue) is a cassette exon. Exons 25B and 26 appear to be mutually exclusive in that only Δ25B+26 and +25BΔ26 variants were detected. Sequence data also demonstrated that a 237-nt, protein-coding portion of exon 38 (defined as exon 38B, green) could be excised as an intron (type E alternative splicing). Additional evidence for alternative processing of the human α_{1G} RNA comes from four clones of a normalized, oligo(dT)-primed infant brain cDNA library. Sequence derived from

these clones (red bars), suggests two polyadenylation sites: an upstream site 321 nt 3' to the stop codon and a downstream site 719 nt 3' to the stop codon. Cleavage at the upstream site would delete 398 nt of the mRNA, defined as exon 38D (purple). Exon 1 includes at least 432 bp of 5' untranslated region and the putative start codon. Introns 2 – 37 are common U2type GTAG introns. Intron 1, like its counterparts in *CACNA1H* (unpublished observations), *CACNA1I* (submitted), and *CACNA1A*, is a rare U12type ATAC intron.

Fig. 4 shows a schematic of the deduced protein products encoded by *CACNA1G*. Like other members of the α_1 subunit family, α_{1G} has a proposed transmembrane topology with four domains (D1 – D4), each consisting of six membrane-spanning segments, a pore loop and cytoplasmic and extracellular connecting loops. The domains are linked by interdomain loops (ID12, ID23, ID34), which, along with the amino- (N) and carboxyl- (C) termini, reside in the cytoplasm. Regions derived from portions of the RNA subject to alternative splicing are highlighted with a blue background, with mutually-exclusive exons 25B and 26 placed side-by-side. The shortest predicted product ($\Delta 14+25B\Delta 26\Delta 34\Delta 35\Delta 38B$) has 2,171 amino-acid (aa) residues; the longest (+14 $\Delta 25B+26+34+35+38B$), 2,377 aa residues. The reported rat α_{1G} aa sequence corresponds to the human (14+25B $\Delta 26\Delta 34\Delta 35+38B$ splice variant and is 93% identical. Additional features of the α_{1G} protein product including residue similarity to the other T α_1 subunits, comparison of splice sites and sites of potential post-translational modification are shown in Fig. 2 and described in the legend.

Six *CACNA1G* exons undergo alternative splicing, leading to a possible 64 splice variants. Analysis of full-length PCR products is underway to determine relative splice-variant abundance. Of note, all potential variants maintain the open reading frame, leave the transmembrane topology intact and, hence, could be translated into plausible protein products. Individual α_{1G} isoforms may play distinct cellular roles by virtue of differences in biophysical behavior, protein-protein interactions, second-messenger-dependent regulation or other isoform-specific properties.

Claims:

1. An isolated and purified α_{1G} subunit of human brain T calcium channel selected from splice variants 1-64 as shown in Table 1.
2. An isolated and purified nucleic acid encoding the α_{1G} subunit of claim 1.
- 5 3. The isolated and purified nucleic acid of claim 2 which comprises a human coding sequence as described in Table 1.
4. An isolated and purified polypeptide which comprises a translated exon selected from the group consisting of 1-38D as shown in Table 2.
5. An isolated and purified nucleic acid which comprises an exon selected
10 from the group consisting of 1-38D as shown in Table 2.
6. An isolated and purified α_{1I} subunit of human brain T calcium channel selected from splice variants 1-8 as shown in Table 3.
7. An isolated and purified nucleic acid encoding the α_{1I} subunit of claim 6.
8. The isolated and purified nucleic acid of claim 7 which comprises a
15 human coding sequence as described in Table 3.
9. An isolated and purified polypeptide which comprises a translated exon selected from the group consisting of 1-37 as shown in Table 4.
10. An isolated and purified nucleic acid which comprises an exon selected from the group consisting of 1-37 as shown in Table 4.
- 20 11. An expression vector comprising the nucleic acid of claim 2.
12. An expression vector comprising the nucleic acid of claim 3.
13. An expression vector comprising the nucleic acid of claim 7.
14. An expression vector comprising the nucleic acid of claim 8.
15. A host cell comprising an expression vector according to claim 11.
- 25 16. A host cell comprising an expression vector according to claim 12.
17. A host cell comprising an expression vector according to claim 13.
18. A host cell comprising an expression vector according to claim 14.
19. A method to identify candidate drugs for treating epilepsy, comprising the steps of:
30 contacting a cell according to claim 15 with a test substance;

measuring uptake by the cell of calcium ions, wherein a test substance which inhibits the uptake by the cell of calcium ions is identified as a candidate drug for treating epilepsy.

5 20. A method to identify candidate drugs for treating epilepsy, comprising the steps of:

 contacting a cell according to claim 16 with a test substance;

 measuring uptake by the cell of calcium ions, wherein a test substance which inhibits the uptake by the cell of calcium ions is identified as a candidate drug for treating epilepsy.

10 21. A method to identify candidate drugs for treating epilepsy, comprising the steps of:

 contacting a cell according to claim 17 with a test substance;

 measuring uptake by the cell of calcium ions, wherein a test substance which inhibits the uptake by the cell of calcium ions is identified as a candidate drug for treating epilepsy.

15 22. A method to identify candidate drugs for treating epilepsy, comprising the steps of:

 contacting a cell according to claim 18 with a test substance;

 measuring uptake by the cell of calcium ions, wherein a test substance which inhibits the uptake by the cell of calcium ions is identified as a candidate drug for treating epilepsy.

FIG. 1





FIG. 2








FIG. 3

FIG. 4



^{5 / 5}
FIG. 5

SEQUENCE LISTING

<110> Mittman, Scott
Agnew, William

<120> Human Brain T Calcium Channel Alpha
Subunit Splice Variants

<130> 01107.81105

<160> 164

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 242

<212> DNA

<213> Homo sapiens

<400> 1

atggacgagg	aggaggatgg	agcggggcgcc	gaggagtcgg	gacagccccc	gagcttcatg	60
cggtcaacg	acctgtcggg	ggccggggggc	cgcccggggc	cggggtcagc	agaaaaggac	120
ccgggcagcg	cggactccga	ggcggagggg	ctgccgtacc	cggcgctggc	cccgggtggt	180
ttcttctact	tgagccagga	cagccgcccc	cggagctggt	gtctccgcac	ggtctgtaac	240
cc						242

<210> 2

<211> 112

<212> DNA

<213> Homo sapiens

<400> 2

ctggtttgag	cgcacagca	tggttggtcat	ccttctcaac	tgcgtgaccc	tgggcatggt	60
ccggccatgc	gaggacatcg	cctgtgactc	ccagcgctgc	cggatcctgc	ag	112

<210> 3

<211> 134

<212> DNA

<213> Homo sapiens

<400> 3

gcctttgatg	acttcatctt	tgccttcttt	gccgtggaga	tggtggtgaa	gatggtggcc	60
ttgggcatct	ttgggaaaaa	gtgttacctg	ggagacactt	ggaaccgggt	tgactttttc	120
atcgcatcg	cagg					134

<210> 4

<211> 98

<212> DNA

<213> Homo sapiens

<400> 4

gatgctggag	tactcgctgg	acctgcagaa	cgtcagcttc	tcagctgtca	ggacagtcgg	60
tgtgctgcga	ccgctcaggg	ccattaaccg	ggtgcccc			98

<210> 5
 <211> 160
 <212> DNA
 <213> Homo sapiens

<400> 5
 gcatgcgcat ccttgtcacg ttgtgtctgg atacgtgcc catgctgggc aacgtcctgc 60
 tgctctgctt cttcgtcttc ttcattctcg gcatcgtcgg cgtccagctg tgggcagggc 120
 tgcttcggaa ccgatgcttc ctacctgaga atttcagcct 160

<210> 6
 <211> 301
 <212> DNA
 <213> Homo sapiens

<400> 6
 cccctgagc gtggacctgg agcgtctatta ccagacagag aacgaggatg agagcccctt 60
 catctgctcc cagccacgcg agaacggcat gcggtcctgc agaagcgtgc ccacgctgcg 120
 cggggacggg ggcgtgggccc caccttgccg tctggactat gaggcctaca acagctccag 180
 caacaccacc tgtgtcaact ggaaccagta ctacaccaac tgctcagcgg gggagcacia 240
 ccccttcaag ggcgccatca actttgacaa cattggctat gcctggatcg ccattctcca 300
 g 301

<210> 7
 <211> 93
 <212> DNA
 <213> Homo sapiens

<400> 7
 gtcacacgc tggagggtcg ggtcgacatc atgtactttg tgatggatgc tcattccttc 60
 tacaatttca tctacttcat cctcctcatc atc 93

<210> 8
 <211> 784
 <212> DNA
 <213> Homo sapiens

<400> 8
 gtgggtcct tcttcatgat caacctgtgc ctgggtggtga ttgccacgca gttctcagag 60
 accaagcagc gggaaagcca gctgatgcgg gagcagcgtg tgcggttcct gtccaacgcc 120
 agcaccctgg ctagcttctc tgagcccgcc agctgctatg aggagctgct caagtacctg 180
 gtgtacatcc ttcgtaaggc agcccgagg ctgggtcagg tctctcgggc agcaggtgtg 240
 cgggttgggc tgetcagcag cccagcacc ctcggggggc aggagacca gccagcagc 300
 agctgctctc gctcccacc cgcctatcc gtccaccacc tgggtcacca ccaccaccac 360
 catcaccacc actaccacct gggcaatggg acgctcaggg cccccgggc cagcccgag 420
 atccaggaca gggatgcca tgggtcccgc aggtctatgc tgccaccacc ctcgacgcct 480
 gccctctccg gggccccccc tgggtggcgca gagtctgtgc acagcttcta ccatgccgac 540
 tgccacttag agccagtcgc ctgccaggcg cccctccca ggtcccatc tgaggcatcc 600
 ggcaggactg tgggcagcgg gaaggtgtat cccaccgtgc acaccagccc tccaccggag 660
 acgctgaagg agaaggcact agtagaggtg gctgccagct ctggggcccc aaccctcacc 720
 agcctcaaca tcccaccgg gccctacagc tccatgcaca agctgctgga gacacagagt 780
 acag 784

<210> 9
 <211> 377

<212> DNA

<213> Homo sapiens

<400> 9

gtgcctgcca aagctcttgc aagatctcca gcccttgctt gaaagcagac agtggagcct	60
gtggtccaga cagctgcccc tactgtgccc gggccggggc aggggaggtg gagctcgccg	120
accgtgaaat gcctgactca gacagcgagg cagtttatga gttcacacag gatgccagc	180
acagcgacct cggggacccc cacagccggc ggcaacggag cctggggcca gatgcagagc	240
ccagctctgt gctggccttc tggaggctaa tctgtgacac cttccgaaag attgtggaca	300
gcaagtactt tggccgggga atcatgatcg ccacctcgtt caacacactc agcatgggca	360
tcgaatacca cgagcag	377

<210> 10

<211> 152

<212> DNA

<213> Homo sapiens

<400> 10

cccaggagagc ttaccaacgc cctagaaatc agcaacatcg tcttcaccag cctctttgcc	60
ctggagatgc tgctgaagct gcttgtgtat ggtccctttg gctacatcaa gaatccctac	120
aacatcttcg atggtgtcat tgtggtcatc ag	152

<210> 11

<211> 186

<212> DNA

<213> Homo sapiens

<400> 11

cgtgtgggag atcgtgggcc agcagggggg cggcctgtcg gtgctgcgga ccttccgcct	60
gatgcgtgtg ctgaagctgg tgcgcttctt gccggcgctg cagcggcagc tgggtgtgtc	120
catgaagacc atggacaacg tggccacctt ctgcatgctg cttatgtctt tcattctcat	180
cttcag	186

<210> 12

<211> 115

<212> DNA

<213> Homo sapiens

<400> 12

catcctgggc atgcatctct tcggctgcaa gtttgctctt gagcgggatg gggacaccct	60
gccagaccgg aagaattttg actccttgct ctgggccatc gtcactgtct ttcag	115

<210> 13

<211> 156

<212> DNA

<213> Homo sapiens

<400> 13

atcctgaccc aggaggactg gaacaaagtc ctctacaatg gtatggcctc cacgtcgtec	60
tgggcggccc tttatttcat tgccctcatg accttcggca actacgtgct cttcaatttg	120
ctggctcgcca ttctggtgga gggcttccag gcggag	156

<210> 14

<211> 69

<212> DNA

<213> Homo sapiens

<400> 14

gaaatcagca aacgggaaga tgcgagtgga cagttaagct gtattcagct gcctgtcgac 60
 tcccagggg 69

<210> 15

<211> 85

<212> DNA

<213> Homo sapiens

<400> 15

ggagatgcc acaagtccga atcagagccc gatttcttct caccagcct ggatggatgat 60
 ggggacagga agaagtgcct ggcct 85

<210> 16

<211> 194

<212> DNA

<213> Homo sapiens

<400> 16

tggtgtccct gggagagcac ccgagctgc ggaagagcct gctgccgcct ctcacatcc 60
 acacggccgc cacacccatg tcgctgccc aagagaccag cacgggcctg ggcgagggc 120
 tgggccctgc gtcgcgccgc accagcagca gcgggtcggc agagcctggg gcggcccacg 180
 agatgaagtc accg 194

<210> 17

<211> 432

<212> DNA

<213> Homo sapiens

<400> 17

cccagcgcgc gcagctctcc gcacagcccc tggagcgctg caagcagctg gaccagcagg 60
 cgctccagcc ggaacagcct cggccgtgca cccagcctga agcggagaag cccaagtgga 120
 gagcggcggt ccctgttgtc gggagaaggc caggagagcc aggatgaaga ggagagctca 180
 gaagaggagc gggccagccc tgcgggcagt gaccatcgcc acaggggggc cctggagcgg 240
 gaggccaaga gttcctttga cctgccagac aactgcagg tgccagggct gcatcgcaact 300
 gccagtggcc gagggctctgc ttctgagcac caggactgca atggcaagtc ggcttcaggg 360
 cgcctggccc gggccctgcg gcctgatgac cccccactgg atggggatga cgccgatgac 420
 gagggcaacc tg 432

<210> 18

<211> 101

<212> DNA

<213> Homo sapiens

<400> 18

agcaaagggg aacgggtccg cgcgtggatc cgagcccgac tccctgcctg ctgcctcgag 60
 cgagactcct ggtcagccta catcttcct cctcagtcga g 101

<210> 19

<211> 124

<212> DNA

<213> Homo sapiens

<400> 19
 gttccgcctc ctgtgtcacc ggatcatcac ccacaagatg ttcgaccacg tggtccttgt 60
 catcatcttc cttaactgca tcaccatcgc catggagcgc cccaaaattg acccccacag 120
 cgct 124

<210> 20
 <211> 69
 <212> DNA
 <213> Homo sapiens

<400> 20
 gaacgcattc tcctgaccct ctccaattac atcttcaccg cagtctttct ggctgaaatg 60
 acagtgaag 69

<210> 21
 <211> 185
 <212> DNA
 <213> Homo sapiens

<400> 21
 gtggtggcac tgggctggtg cttcggggag caggcgtacc tgcggagcag ttggaacgtg 60
 ctggacgggc tgttgggtgct catctccgtc atcgacattc tgggtgccat ggtctctgac 120
 agcggcacca agatcctggg catgctgagg gtgctgcggc tgetgcggac cctgcgcccc 180
 ctgag 185

<210> 22
 <211> 127
 <212> DNA
 <213> Homo sapiens

<400> 22
 ggtgatcagc cgggcgcagg ggctgaagct ggtggtggag acgctgatgt cctcactgaa 60
 acccatcggc aacattgtag tcattctgctg tgccttcttc atcattttcg gcatcttggg 120
 ggtgcag 127

<210> 23
 <211> 126
 <212> DNA
 <213> Homo sapiens

<400> 23
 ctcttcaaag ggaagttttt cgtgtgccag ggcgaggata ccaggaacat caccaataaa 60
 tcggactgtg ccgagggcag ttaccggtgg gtccggcaca agtacaactt tgacaacctt 120
 ggccag 126

<210> 24
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 24
 gccttgatgt ccctgttcgt tttggcctcc aaggatggtt ggggtggacat catgtacgat 60
 gggctggatg ctgtgggcgt ggaccagcag 90

<210> 25

<211> 193
 <212> DNA
 <213> Homo sapiens

<400> 25
 cccatcatga accacaaccc ctggatgctg ctgtacttca tctcgttcct gtcattgtg 60
 gccttctttg tcctgaacat gtttgtgggt gtggtgggtg agaacttcca caagtgtcgg 120
 cagcaccagg aggaagagga ggcccggcgg cgggaggaga agcgcctacg aagactggag 180
 aaaaagagaa gga 193

<210> 26
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 26
 gtaaggagaa gcagatggct g 21

<210> 27
 <211> 54
 <212> DNA
 <213> Homo sapiens

<400> 27
 atctaagtct ggacgatgta attgcttccg gcagctcagc cagcgtgcg tcag 54

<210> 28
 <211> 152
 <212> DNA
 <213> Homo sapiens

<400> 28
 aagcccagtg caaaccttac tactccgact actcccgtt ccggctcttc gtccaccact 60
 tgtgcaccag ccactacctg gacctcttca tcacaggtgt catcgggctg aacgtgggtca 120
 ccatggccat ggagcactac cagcagcccc ag 152

<210> 29
 <211> 110
 <212> DNA
 <213> Homo sapiens

<400> 29
 attctggatg aggctctgaa gatctgcaac tacatcttca ctgtcatctt tgtcttggag 60
 tcagttttca aacttgtggc ctttggtttc cgtcggttct tccaggacag 110

<210> 30
 <211> 134
 <212> DNA
 <213> Homo sapiens

<400> 30
 gtggaaccag ctggacctgg ccattgtgct gctgtccatc atgggcatca cgctggagga 60
 aatcgaggtc aacgcctcgc tgcccatcaa cccaccatc atccgcatca tgaggggtgct 120
 gcgcattgcc cgag 134

<210> 31
 <211> 71
 <212> DNA
 <213> Homo sapiens

<400> 31
 tgctgaagct gctgaagatg gctgtgggca tgcgggcgct gctggacacg gtgatgcagg 60
 ccctgccccca g 71

<210> 32
 <211> 79
 <212> DNA
 <213> Homo sapiens

<400> 32
 gtgggggaacc tgggacttct cttcatgttg ttgtttttca tctttgcagc tctgggcgtg 60
 gagctctttg gagacctgg 79

<210> 33
 <211> 122
 <212> DNA
 <213> Homo sapiens

<400> 33
 agtgtgacga gacacacccc tgtgagggcc tggggcgtca tgccaccttt cggaactttg 60
 gcatggcctt cctaaccctc ttccgagtct ccacaggtga caattggaat ggcattatga 120
 ag 122

<210> 34
 <211> 354
 <212> DNA
 <213> Homo sapiens

<400> 34
 gacaccctcc gggactgtga ccaggagtcc acctgctaca acacgggtcat ctgcctatc 60
 tacttttgtt ccttcgtgct gacggcccag ttcgtgctag tcaacgtggt gatcgccgtg 120
 ctgatgaagc acctggagga gagcaacaag gaggccaagg aggaggccga gctagaggct 180
 gagctggagc tggagatgaa gacctcagc cccagcccc actcgccact gggcagcccc 240
 ttctctgtgc ctggggtcga gggccccgac agccccgaca gcccgaagcc tggggctctg 300
 caccagcgg cccacgcgag atcagcctcc cacttttccc tggagcacc cag 354

<210> 35
 <211> 144
 <212> DNA
 <213> Homo sapiens

<400> 35
 gacaggcagc tgtttgacac catatccctg ctgatccagg gctccctgga gtgggagctg 60
 aagctgatgg acgagctggc agggcccagg ggccagccct ctgccttccc ttctgcccc 120
 agcctgggag gctccgaccc acag 144

<210> 36
 <211> 135
 <212> DNA
 <213> Homo sapiens

<400> 36
atccctctag ctgagatgga ggctctgtct ctgacgtcag agattgtgtc tgaaccgtcc 60
tgctctctag ctctgacgga tgactctttg cctgatgaca tgcacacact cttacttagt 120
gccctggaga gcaat 135

<210> 37
<211> 169
<212> DNA
<213> Homo sapiens

<400> 37
atgcagcccc accccacgga gctgccagga ccagacttac tgactgtgcg gaagtctggg 60
gtcagccgaa cgactctct gcccaatgac agctacatgt gtcggcatgg gagcactgcc 120
gagggggcccc tgggacacag gggctggggg ctccccaaag ctcagtcag 169

<210> 38
<211> 170
<212> DNA
<213> Homo sapiens

<400> 38
gtcccgcttt gtccgttcac tcccagccag cagataccag ctacatcctg cagcttccca 60
aagatgcacc tcactgtctc cagccccaca gcgccccaac ctggggcacc atccccaaac 120
tgccccacc aggacgtctc cttttggctc agaggccact caggcgccag 170

<210> 39
<211> 66
<212> DNA
<213> Homo sapiens

<400> 39
gcagcaataa ggactgactc cttggacgtt caggggtctgg gcagccggga agacctgctg 60
gcagag 66

<210> 40
<211> 237
<212> DNA
<213> Homo sapiens

<400> 40
gtgagtgggc cctccccgcc cctggcccg gcctactctt tctggggcca gtcaagtacc 60
caggcacagc agcactcccg cagccacagc aagatctcca agcactgac cccgccagcc 120
ccttgcccag gcccagaacc caactggggc aaggggccctc cagagaccag aagcagctta 180
gagttggaca cggagctgag ctggatttca ggagacctcc tgccccctgg cggccag 237

<210> 41
<211> 753
<212> DNA
<213> Homo sapiens

<400> 41
gaggagcccc catccccacg ggacctgaag aagtgtctaca gcgtggaggc ccagagctgc 60
cagcgccggc ctacgtcctg gctggatgag cagaggagac actctatcgc cgtcagctgc 120
ctggacagcg gctcccaacc ccacctgggc acagaccctc ctaaccttgg gggccagcct 180
cttggggggc ctgggagccg gcccaagaaa aaactcagcc cgcttagtat caccatagac 240

ccccccgaga	gccaaaggtcc	tgggaccccg	cccagccctg	gtatctgcct	ccggaggagg	300
gctccgtcca	gcgactccaa	ggatcccttg	gcctctggcc	cccctgacag	catggctgcc	360
tggccctccc	caaagaaaga	tgtgtgagt	ctctccggtt	tatcctctga	cccagcagac	420
ctggacccct	gagtcctgcc	ccactttccc	actcaccttt	ctccactggg	tgccaagtcc	480
tagctcctcc	tcctgggcta	tattcctgac	aaaagtcca	tatagacacc	aaggaggcgg	540
aggcgctcct	ccctgcctca	gtggctctgg	gtacctgcaa	gcagaacttc	caaagagagt	600
taaaagcagc	agccccggca	actctggctc	caggcagaag	gagaggcccg	gtgcagctga	660
ggttccccgac	accagaagct	gttgggagaa	agcaatacgt	ttgtgcagaa	tctctatgta	720
tattctattt	tattaaatta	attgaatcta	gta			753

<210> 42
 <211> 402
 <212> DNA
 <213> Homo sapiens

<400> 42						
tatgcgggat	gtacgacatt	ttgtgactga	agagacttgt	ttcctttctac	ttttatgtgt	60
ctcagaatat	ttttgaggcg	aaggcgtctg	tctcttggct	atttttaacct	aaaataacag	120
tctagttata	ttccctcttc	ttgcaaagca	caagctggga	ccgcgagcac	attgcagccc	180
caacggtggc	ccatcttcag	cggagagcga	gaaccatttt	ggaaactgta	atgtaactta	240
ttttttcctt	taacctcgtc	atcattttct	gtagggaaaa	aaaaaagaaa	aagaaaaaat	300
gagattttac	aagtgaatg	gaaccttttt	atatatacat	acatacatat	ctatctatct	360
atctatatat	atataaaata	aagtaatttt	cctaaataaa	aa		402

<210> 43
 <211> 236
 <212> DNA
 <213> Homo sapiens

<400> 43						
atggctgaga	gcgcctcccc	gcctcctca	tctgcagcag	ccccagccgc	tgagccagga	60
gtcaccacgg	agcagcccg	accccgagc	ccccatcct	ccccgccagg	cctggaggag	120
cctctggatg	gagctgatcc	tcatgtccca	caccagacc	tggcgctat	tgccttcttc	180
tgctcgcgac	agaccaccag	cccccggaac	tggtgcatca	agatggtgtg	caaccc	236

<210> 44
 <211> 112
 <212> DNA
 <213> Homo sapiens

<400> 44						
gtggtttgaa	tgtgtcagca	tgctggtgat	cctgctgaac	tgctgacac	ttggcatgta	60
ccagccgtgc	gacgacatgg	actgcctgtc	cgaccgtgc	aagatcctgc	ag	112

<210> 45
 <211> 134
 <212> DNA
 <213> Homo sapiens

<400> 45						
gtctttgatg	acttcatctt	tatcttcttt	gccatggaga	tggtgctcaa	gatggtggcc	60
ctggggattt	ttggcaagaa	gtgctacctc	ggggacacat	ggaaccgcct	ggatttcttc	120
atcgtcatgg	cagg					134

<210> 46

<211> 98
 <212> DNA
 <213> Homo sapiens

<400> 46
 gatggctcgag tactccctgg accttcagaa catcaacctg tcagccatcc gcaccgtgcg 60
 cgtcctgagg cccctcaaag ccatcaaccg cgtgccca 98

<210> 47
 <211> 160
 <212> DNA
 <213> Homo sapiens

<400> 47
 gtatgcgat cctggatgaac ctgctcctgg acacactgcc catgctgggg aatgtcctgc 60
 tgctctgctt ctttgtcttc ttcattcttg gcatcatagg tgtgcagctc tgggcggggc 120
 tgctgcgtaa cgcgtgcttc ctggaggaga acttcaccat 160

<210> 48
 <211> 316
 <212> DNA
 <213> Homo sapiens

<400> 48
 acaaggggat gtggccttgc cccatacta ccagccggag gaggatgatg agatgccctt 60
 catctgctcc ctgtcgggag acaatgggat aatgggctgc catgagatcc ccccgctcaa 120
 ggagcagggc cgtgagtgtt gcctgtccaa ggacgacgtc tacgactttg gggcggggag 180
 ccaggacctc aatgccagcg gcctctgtgt caactggaac cgttactaca atgtgtgccg 240
 cacgggcagc gccaaccccc acaagggtgc catcaacttt gacaacatcg gttatgcttg 300
 gattgtcatc ttccag 316

<210> 49
 <211> 93
 <212> DNA
 <213> Homo sapiens

<400> 49
 gtgatcactc tggaaggctg ggtggagatc atgtactacg tgatggatgc tcaactcttc 60
 tacaacttca tctacttcat cctgcttata ata 93

<210> 50
 <211> 313
 <212> DNA
 <213> Homo sapiens

<400> 50
 gtgggctcct tcttcatgat caacctgtgc ctggtgttca tagcgaccca gttctcggag 60
 accaagcaac gggagcaccg gctgatgctg gagcagcggc agcgctacct gtcctccagc 120
 acggtggcca gctacgccga gcctggcgac tgctacgagg agatcttcca gtatgtctgc 180
 cacatcctgc gcaaggccaa gcgcgcggcc ctgggcctct accaggccct gcagagccgg 240
 cgccaggccc tgggcccggg ggccccggcc cccgccaaac ctgggcccga cgccaaggag 300
 ccccggcact acc 313

<210> 51
 <211> 105

<212> DNA

<213> Homo sapiens

<400> 51

atgggaagac taagggtcag ggagatgaag ggagacatct cggaagccgg cattgccaga	60
ctttgcatgg gcctgcctcc cctggaaatg atcactcggg aagag	105

<210> 52

<211> 425

<212> DNA

<213> Homo sapiens

<400> 52

agctgtgccc gcaacatagc cccctggatg cgacgcccc caccctggtg cagcccatcc	60
ccgccacgct ggcttccgat cccgccagct gcccttgctg ccagcatgag gacggccggc	120
ggccctcggg cctgggcagc accgactcgg gccaggaggg ctcgggctcc gggagctccg	180
ctggtggcga ggacgaggcg gatggggacg gggcccggag cagcgaggac ggagcctcct	240
cagaactggg gaaggaggag gaggaggagg agcaggcgga tggggcggtc tggctgtgcg	300
gggatgtgtg gcgggagacg cgagccaagc tgcgcggcat cgtggacagc aagtacttca	360
accggggcat catgatggcc atcctgggtca acaccgtcag catgggcatc gagcaccacg	420
agcag	425

<210> 53

<211> 152

<212> DNA

<213> Homo sapiens

<400> 53

ccggaggagc tgaccaacat cctggagatc tgcaatgtgg tcttcaccag catgtttgcc	60
ctggagatga tcctgaagct ggctgcattt gggctcttcg actacctgag taaccctac	120
aacatcttcg acagcatcat tgatcatcag ag	152

<210> 54

<211> 186

<212> DNA

<213> Homo sapiens

<400> 54

catctgggag atcgtggggc aggcggacgg tgggctgtcg gtgctgcgga ccttccggct	60
gctgcgcgtg ctgaaactgg tgcgttcat gccctgccctg cggcgccagc tcgtggtgct	120
catgaagacc atggacaacg tggccacctt ctgcatgctg ctcatgctct tcatttcat	180
cttcag	186

<210> 55

<211> 118

<212> DNA

<213> Homo sapiens

<400> 55

catccttggg atgcatatct ttggctgcaa gttcagcctc cgcacggaca ctggagacac	60
ggcgccgac aggaagaact tcgactccct gctgtggggc atcgctcactg tgttccag	118

<210> 56

<211> 156

<212> DNA

<213> Homo sapiens

<400> 56

atcctcaccc	aggaggactg	gaacgtcggt	ctctacaatg	gcattggcctc	catttctccc	60
tgggcctccc	tctactttgt	cgccctcatg	accttcggca	actatgtgct	cttcaacctg	120
ctgggtggcca	tcctgggtgga	gggcttccag	gcggag			156

<210> 57

<211> 94

<212> DNA

<213> Homo sapiens

<400> 57

ggtgacgcca	atcgctccta	ctcggacgag	gaccagagct	catccaacat	agaagagttt	60
gataagctcc	aggaaggcct	ggacagcagc	ggag			94

<210> 58

<211> 203

<212> DNA

<213> Homo sapiens

<400> 58

atcccaagct	ctgcccacac	cccatgaccc	ccaatgggca	cctggacccc	agtctccac	60
tgggtgggca	cctaggtcct	gctggggctg	cgggacctgc	ccccgactc	tactgcagc	120
cggaacccat	gctgggtggc	ctgggctccc	gaaagagcag	tgcatgtct	ctagggagga	180
tgagctatga	ccagcgtccc	ctg				203

<210> 59

<211> 471

<212> DNA

<213> Homo sapiens

<400> 59

tcagctccc	ggagctccta	ctacggggcca	tggggcgcca	gcgcggcctg	ggccagccgt	60
cgctccagct	ggaacagcct	caagcacaag	ccgcgcgtcg	cggagcatga	gtccctgctc	120
tctgcggagc	gcggcgggcg	cgcccgggtc	tgcgagggtg	ccgcggacga	ggggccgccc	180
cgggccgcac	ccctgcacac	cccacacgcc	caccacattc	atcacggggc	ccatctggcg	240
caccgccacc	gccaccaccg	ccggacgctg	tcctctgaca	acagggactc	ggtggacctg	300
gccgagctgg	tgcccgcggt	gggcgcccac	ccccggggcg	cctggagggc	ggcaggcccc	360
gcccccgggc	atgaggactg	caatggcagg	atgccagca	tcgccaaga	cgtcttcacc	420
aagatggggc	accgcgggga	tcgcggggag	gatgaggagg	aaatcgacta	c	471

<210> 60

<211> 101

<212> DNA

<213> Homo sapiens

<400> 60

accctgtgct	tccgcgtccg	caagatgatc	gacgtctata	agcccgactg	gtgcgaggtc	60
cgcgaagact	ggtctgtcta	cctcttctct	cccgagaaca	g		101

<210> 61

<211> 124

<212> DNA

<213> Homo sapiens

<400> 61
 gttccgggtc ctgtgtcaga ccattattgc ccacaaactc ttcgactacg tcgtcctggc 60
 cttcatcttt ctcaactgca tcaccatcgc cctggagcgg cctcagatcg aggccggcag 120
 cacc 124

<210> 62
 <211> 69
 <212> DNA
 <213> Homo sapiens

<400> 62
 gaacgcatct ttctcaccgt gtccaactac atcttcacgg ccattcttcgt gggcgagatg 60
 acattgaag 69

<210> 63
 <211> 185
 <212> DNA
 <213> Homo sapiens

<400> 63
 gtagtctcgc tgggcctgta cttcggcgag caggcgtacc tacgcagcag ctggaacgtg 60
 ctggatgggt ttcttgtctt cgtgtccatc atcgacatcg tgggtgccct ggcctcagcc 120
 gggggagcca agatcttggg ggtcctccga gtcttgccgc tcctgcgcac cctacgcccc 180
 ctgcg 185

<210> 64
 <211> 127
 <212> DNA
 <213> Homo sapiens

<400> 64
 tgtcatcagc cgggcgcggg gcctgaagct ggtggtggag aactcatct cctccctcaa 60
 gcccatcggc aacatcgtgc tcattctgctg tgccttcttc atcatctttg gcattcctggg 120
 agtgcag 127

<210> 65
 <211> 126
 <212> DNA
 <213> Homo sapiens

<400> 65
 ctcttcaagg gcaagttcta ccaactgtctg ggcgtggaca cccgcaacat caccaaccgc 60
 tcggactgca tggccgcca ctaccgctgg gtccatcaca aatacaactt cgacaacctg 120
 ggccag 126

<210> 66
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 66
 gctctgatgt ccctctttgt cctggcatcc aaggatgggt gggatgaacat catgtacaat 60
 ggactggatg ctgttgctgt ggaccagcag 90

<210> 67

<211> 193

<212> DNA

<213> Homo sapiens

<400> 67

cctgtgacca accacaaccc ctggatgctg ctgtacttca tctccttcc	gctcatcgtc	60
agcttctttg tgctcaacat gtttgtgggt gtcgtgggtg agaacttcca	caagtgcggg	120
cagcaccagg aggctgaaga ggcacggcgg cgtgaggaga agcggctgcg	gcgcctggag	180
aagaagcgcc gga		193

<210> 68

<211> 152

<212> DNA

<213> Homo sapiens

<400> 68

aggcccagcg gctgccctac tatgccacct attgtcacac ccggtgctc	atccactcca	60
tgtgcaccag ccactacctg gacatcttca tcaccttcac catctgcctc	aacgtgggtca	120
ccatgtccct ggagcactac aatcagccca cg		152

<210> 69

<211> 110

<212> DNA

<213> Homo sapiens

<400> 69

tccctggaga cagccctcaa gtactgcaac tatatgttca ccactgtctt	tgtgctggag	60
gctgtgctga agctgggtggc atttggctctg aggcgcttct tcaaggaccg		110

<210> 70

<211> 134

<212> DNA

<213> Homo sapiens

<400> 70

atggaaccag ctggacctgg ccattgtgct actgtcagtc atgggcatca	ccctggagga	60
gatcgagatc aatgcggccc tgcccatcaa tcccaccatc atccgcatca	tgagggttct	120
gcgcattgcc cgag		134

<210> 71

<211> 71

<212> DNA

<213> Homo sapiens

<400> 71

tgctgaagct gttgaagatg gccacaggaa tgcgggccct gctggacacg	gtgggtgcaag	60
ctttgcecca g		71

<210> 72

<211> 79

<212> DNA

<213> Homo sapiens

<400> 72

gtgggcaacc tgggcctcct cttcatgctg ctcttcttca tctatgctgc	tctcgggggtg	60
--	-------------	----

gagctctttg ggaagctgg 79

<210> 73
 <211> 122
 <212> DNA
 <213> Homo sapiens

<400> 73
 tctgcaacga cgagaacccg tgcgagggca tgagccggca tgccaccttc gagaacttcg 60
 gcatggcctt cctcacactc ttccaggtct ccacgggtga caactggaac gggatcatga 120
 ag 122

<210> 74
 <211> 339
 <212> DNA
 <213> Homo sapiens

<400> 74
 gacacgctgc gggactgcac ccacgacgag cgcagctgcc tgagcagcct gcagtttgtg 60
 tcgccgctgt acttcgtgag cttcgtgctc accgcgcagt tcgtgctcat caacgtgggtg 120
 gtggctgtgc tcataagca cctggacgac agcaacaagg aggcgcagga ggacgcccag 180
 atggatgccg agctcgagct ggagatggcc catggcctgg gccctggccc gaggtgcct 240
 accggctccc cgggcgcccc tggccgaggg ccgggagggg cgggcggcgg gggcgacacc 300
 gagggcggtc tgtccggcg ctgctactcg cctgcccag 339

<210> 75
 <211> 39
 <212> DNA
 <213> Homo sapiens

<400> 75
 gagaacctgt ggctggacag cgtctcttta atcatcaag 39

<210> 76
 <211> 108
 <212> DNA
 <213> Homo sapiens

<400> 76
 gactccttgg agggggagct gaccatcatc gacaacctgt cgggctccat cttccaccac 60
 tactcctcgc ctgccggctg caagaagtgt caccacgaca agcaagag 108

<210> 77
 <211> 123
 <212> DNA
 <213> Homo sapiens

<400> 77
 gtgcagctgg ctgagacgga ggccttctcc ctgaactcag acaggctctc gtccatcctg 60
 ctgggtgacg acctgagtct cgaggacccc acagcctgcc cacctggccg caaagacagc 120
 aag 123

<210> 78
 <211> 166
 <212> DNA

<213> Homo sapiens

<400> 78

ggtgagctgg acccacctga gcccatgcgt gtgggagacc tgggcgaatg cttcttcccc	60
ttgtcctcta cggccgtctc gccggatcca gagaacttcc tgtgtgagat ggaggagatc	120
ccattcaacc ctgtccggtc ctggctgaaa catgacagca gtcaag	166

<210> 79

<211> 197

<212> DNA

<213> Homo sapiens

<400> 79

cacccccaaag tcccttctcc ccggatgcct ccagccctct cctgcccattg ccagccgagt	60
tcttccaccc tgagtggtct gccagccaga aaggccaga aaagggcact ggcactggaa	120
ccctcccaaa gattgcgtct cagggctcct gggcatctct gcggtcacca agggtaact	180
gtaccctcct ccggcag	197

<210> 80

<211> 713

<212> DNA

<213> Homo sapiens

<400> 80

gtaccgacac ctcccaggcc ctagagcact ggtctgtggg caaggggcag gatctaagcc	60
aggcctggaa gtccaaggga ctgggagggg aaggacccaa ccaaaggccg agggcaccac	120
cgtgcaaggg ggtttgggaa cgctgggggtg acgctgagac tggaggggga ggtggcactg	180
gggcggatgg agtgggcggg gctgggtcct ggggacagca gagtgtgggg aggaccccaa	240
ggcgggtctg gaagaggcct gtgatcccta gcttgagggg aggggaggag agggaggagga	300
gtactggagg ttttgagggg tggcgggggtg ctggcagtggt ggaggacacc ctgggtgctc	360
tgggtgggtg tgagtggggg cttgattact aggaatggag gtgggagggc ggggtctggtg	420
gatgagaagc ctccgggtgc aggggtcccc gtactggatt ggccagggcc acagccctcc	480
taccacggg caccagagg tctgaagcac tgaggggtcc gctgtggggg tggggaatg	540
gggcggggcc ggctccaca gtgagtgcag ttgattcact ggggtactgt ctgaccgctc	600
acaccagggt gtgtgctctg gcgggcagga cacaactcc ctgcctgccg ggctcactgt	660
ttagtgctga gagtgcgtg cctgggtgca ggagggatga taacaaaat aaa	713

<210> 81

<211> 963

<212> DNA

<213> Homo sapiens

<400> 81

gccaccggga ggcacagctc gctggacgcc agccccagca gctccgcggg cagcctgcag	60
accacgctcg aggacagcct gaccctgagc gacagcccc ggctgcccct ggggccgccc	120
gcgctgctc caggaccccg ggccggcctg tccccgcgg ctcgcccgg cctgagcctg	180
cgcggccggg gcctcttcag cctgcggggg ctgcggggcg atcagcgag ccacagcagc	240
gggggtcca ccagcccggtg ctgcacccac cagactcca tggacccctc ggacgaggag	300
ggccgcgggtg gcgcggggcg cgggggcggc ggcagcgagc actcggagac cctcagcagc	360
ctctcgctca cctccctctt ctgcccgcgg ccccgccggc cagccccgg cctcagcccc	420
gccaggaagt tcagcagcac cagcagcctg gccgcccccg gccgccccca cgcgcggcc	480
ctggcccacg gcctggcccc gagcccctcg tgggcggcgg accgcagcaa ggaccccccc	540
ggccggggcac cgctgcccct gggcctgggc cccttggcgc ccccgccgca accgctcccc	600
ggagagctgg agccgggaga cgcggccagc aagaggaaga gatgagggtc gcaggggccc	660
ccggccgccc accgcccgc cgtctcacc ttctttacct caggagccag gagcagacag	720

```

caataacttcg tccacacctg ggatcgcgca gggcccgag ggcacagcg cccgacagcc 780
gggctgagcg gagtctgggt tagccaggcc tgcgtggccc atggtggccc ttccagtgc 840
tatacatata tatatatata tatatgcata tatatatata tatgtgtata 900
cacacacaca tagacagaca tatatatata tatttatatt ttttactgag agcttatgac 960
ttc 963

```

<210> 82
 <211> 81
 <212> PRT
 <213> Homo sapiens

<400> 82

```

Met Asp Glu Glu Glu Asp Gly Ala Gly Ala Glu Glu Ser Gly Gln Pro
1          5          10          15
Arg Ser Phe Met Arg Leu Asn Asp Leu Ser Gly Ala Gly Gly Arg Pro
20        25        30
Gly Pro Gly Ser Ala Glu Lys Asp Pro Gly Ser Ala Asp Ser Glu Ala
35        40        45
Glu Gly Leu Pro Tyr Pro Ala Leu Ala Pro Val Val Phe Phe Tyr Leu
50        55        60
Ser Gln Asp Ser Arg Pro Arg Ser Trp Cys Leu Arg Thr Val Cys Asn
65        70        75        80
Pro

```

<210> 83
 <211> 37
 <212> PRT
 <213> Homo sapiens

<400> 83

```

Trp Phe Glu Arg Ile Ser Met Leu Val Ile Leu Leu Asn Cys Val Thr
1          5          10          15
Leu Gly Met Phe Arg Pro Cys Glu Asp Ile Ala Cys Asp Ser Gln Arg
20        25        30
Cys Arg Ile Leu Gln
35

```

<210> 84
 <211> 45
 <212> PRT
 <213> Homo sapiens

<400> 84

```

Ala Phe Asp Asp Phe Ile Phe Ala Phe Phe Ala Val Glu Met Val Val
1          5          10          15
Lys Met Val Ala Leu Gly Ile Phe Gly Lys Lys Cys Tyr Leu Gly Asp
20        25        30
Thr Trp Asn Arg Leu Asp Phe Phe Ile Val Ile Ala Gly
35        40        45

```

<210> 85
 <211> 32
 <212> PRT
 <213> Homo sapiens

<400> 85

Met Leu Glu Tyr Ser Leu Asp Leu Gln Asn Val Ser Phe Ser Ala Val
 1 5 10 15
 Arg Thr Val Arg Val Leu Arg Pro Leu Arg Ala Ile Asn Arg Val Pro
 20 25 30

<210> 86

<211> 54

<212> PRT

<213> Homo sapiens

<400> 86

Ser Met Arg Ile Leu Val Thr Leu Leu Leu Asp Thr Leu Pro Met Leu
 1 5 10 15
 Gly Asn Val Leu Leu Leu Cys Phe Phe Val Phe Phe Ile Phe Gly Ile
 20 25 30
 Val Gly Val Gln Leu Trp Ala Gly Leu Leu Arg Asn Arg Cys Phe Leu
 35 40 45
 Pro Glu Asn Phe Ser Leu
 50

<210> 87

<211> 100

<212> PRT

<213> Homo sapiens

<400> 87

Pro Leu Ser Val Asp Leu Glu Arg Tyr Tyr Gln Thr Glu Asn Glu Asp
 1 5 10 15
 Glu Ser Pro Phe Ile Cys Ser Gln Pro Arg Glu Asn Gly Met Arg Ser
 20 25 30
 Cys Arg Ser Val Pro Thr Leu Arg Gly Asp Gly Gly Gly Gly Pro Pro
 35 40 45
 Cys Gly Leu Asp Tyr Glu Ala Tyr Asn Ser Ser Ser Asn Thr Thr Cys
 50 55 60
 Val Asn Trp Asn Gln Tyr Tyr Thr Asn Cys Ser Ala Gly Glu His Asn
 65 70 75 80
 Pro Phe Lys Gly Ala Ile Asn Phe Asp Asn Ile Gly Tyr Ala Trp Ile
 85 90 95
 Ala Ile Phe Gln
 100

<210> 88

<211> 31

<212> PRT

<213> Homo sapiens

<400> 88

Val Ile Thr Leu Glu Gly Trp Val Asp Ile Met Tyr Phe Val Met Asp
 1 5 10 15
 Ala His Ser Phe Tyr Asn Phe Ile Tyr Phe Ile Leu Leu Ile Ile
 20 25 30

<210> 89

<211> 261

<212> PRT

<213> Homo sapiens

<400> 89

Val Gly Ser Phe Phe Met Ile Asn Leu Cys Leu Val Val Ile Ala Thr
 1 5 10 15
 Gln Phe Ser Glu Thr Lys Gln Arg Glu Ser Gln Leu Met Arg Glu Gln
 20 25 30
 Arg Val Arg Phe Leu Ser Asn Ala Ser Thr Leu Ala Ser Phe Ser Glu
 35 40 45
 Pro Gly Ser Cys Tyr Glu Glu Leu Leu Lys Tyr Leu Val Tyr Ile Leu
 50 55 60
 Arg Lys Ala Ala Arg Arg Leu Ala Gln Val Ser Arg Ala Ala Gly Val
 65 70 75 80
 Arg Val Gly Leu Leu Ser Ser Pro Ala Pro Leu Gly Gly Gln Glu Thr
 85 90 95
 Gln Pro Ser Ser Ser Cys Ser Arg Ser His Arg Arg Leu Ser Val His
 100 105 110
 His Leu Val His His His His His His His His Tyr His Leu Gly
 115 120 125
 Asn Gly Thr Leu Arg Ala Pro Arg Ala Ser Pro Glu Ile Gln Asp Arg
 130 135 140
 Asp Ala Asn Gly Ser Arg Arg Leu Met Leu Pro Pro Ser Thr Pro
 145 150 155 160
 Ala Leu Ser Gly Ala Pro Pro Gly Gly Ala Glu Ser Val His Ser Phe
 165 170 175
 Tyr His Ala Asp Cys His Leu Glu Pro Val Arg Cys Gln Ala Pro Pro
 180 185 190
 Pro Arg Ser Pro Ser Glu Ala Ser Gly Arg Thr Val Gly Ser Gly Lys
 195 200 205
 Val Tyr Pro Thr Val His Thr Ser Pro Pro Pro Glu Thr Leu Lys Glu
 210 215 220
 Lys Ala Leu Val Glu Val Ala Ala Ser Ser Gly Pro Pro Thr Leu Thr
 225 230 235 240
 Ser Leu Asn Ile Pro Pro Gly Pro Tyr Ser Ser Met His Lys Leu Leu
 245 250 255
 Glu Thr Gln Ser Thr
 260

<210> 90

<211> 126

<212> PRT

<213> Homo sapiens

<400> 90

Gly Ala Cys Gln Ser Ser Cys Lys Ile Ser Ser Pro Cys Leu Lys Ala
 1 5 10 15
 Asp Ser Gly Ala Cys Gly Pro Asp Ser Cys Pro Tyr Cys Ala Arg Ala
 20 25 30
 Gly Ala Gly Glu Val Glu Leu Ala Asp Arg Glu Met Pro Asp Ser Asp
 35 40 45
 Ser Glu Ala Val Tyr Glu Phe Thr Gln Asp Ala Gln His Ser Asp Leu
 50 55 60
 Arg Asp Pro His Ser Arg Arg Gln Arg Ser Leu Gly Pro Asp Ala Glu
 65 70 75 80

Pro Ser Ser Val Leu Ala Phe Trp Arg Leu Ile Cys Asp Thr Phe Arg
 85 90 95
 Lys Ile Val Asp Ser Lys Tyr Phe Gly Arg Gly Ile Met Ile Ala Ile
 100 105 110
 Leu Val Asn Thr Leu Ser Met Gly Ile Glu Tyr His Glu Gln
 115 120 125

<210> 91
 <211> 51
 <212> PRT
 <213> Homo sapiens

<400> 91
 Pro Glu Glu Leu Thr Asn Ala Leu Glu Ile Ser Asn Ile Val Phe Thr
 1 5 10 15
 Ser Leu Phe Ala Leu Glu Met Leu Leu Lys Leu Leu Val Tyr Gly Pro
 20 25 30
 Phe Gly Tyr Ile Lys Asn Pro Tyr Asn Ile Phe Asp Gly Val Ile Val
 35 40 45
 Val Ile Ser
 50

<210> 92
 <211> 62
 <212> PRT
 <213> Homo sapiens

<400> 92
 Val Trp Glu Ile Val Gly Gln Gln Gly Gly Gly Leu Ser Val Leu Arg
 1 5 10 15
 Thr Phe Arg Leu Met Arg Val Leu Lys Leu Val Arg Phe Leu Pro Ala
 20 25 30
 Leu Gln Arg Gln Leu Val Val Leu Met Lys Thr Met Asp Asn Val Ala
 35 40 45
 Thr Phe Cys Met Leu Leu Met Leu Phe Ile Phe Ile Phe Ser
 50 55 60

<210> 93
 <211> 38
 <212> PRT
 <213> Homo sapiens

<400> 93
 Ile Leu Gly Met His Leu Phe Gly Cys Lys Phe Ala Ser Glu Arg Asp
 1 5 10 15
 Gly Asp Thr Leu Pro Asp Arg Lys Asn Phe Asp Ser Leu Leu Trp Ala
 20 25 30
 Ile Val Thr Val Phe Gln
 35

<210> 94
 <211> 52
 <212> PRT
 <213> Homo sapiens

<400> 94

Ile Leu Thr Gln Glu Asp Trp Asn Lys Val Leu Tyr Asn Gly Met Ala
 1 5 10 15
 Ser Thr Ser Ser Trp Ala Ala Leu Tyr Phe Ile Ala Leu Met Thr Phe
 20 25 30
 Gly Asn Tyr Val Leu Phe Asn Leu Leu Val Ala Ile Leu Val Glu Gly
 35 40 45
 Phe Gln Ala Glu
 50

<210> 95

<211> 23

<212> PRT

<213> Homo sapiens

<400> 95

Glu Ile Ser Lys Arg Glu Asp Ala Ser Gly Gln Leu Ser Cys Ile Gln
 1 5 10 15
 Leu Pro Val Asp Ser Gln Gly
 20

<210> 96

<211> 28

<212> PRT

<213> Homo sapiens

<400> 96

Gly Asp Ala Asn Lys Ser Glu Ser Glu Pro Asp Phe Phe Ser Pro Ser
 1 5 10 15
 Leu Asp Gly Asp Gly Asp Arg Lys Lys Cys Leu Ala
 20 25

<210> 97

<211> 65

<212> PRT

<213> Homo sapiens

<400> 97

Leu Val Ser Leu Gly Glu His Pro Glu Leu Arg Lys Ser Leu Leu Pro
 1 5 10 15
 Pro Leu Ile Ile His Thr Ala Ala Thr Pro Met Ser Leu Pro Lys Ser
 20 25 30
 Thr Ser Thr Gly Leu Gly Glu Ala Leu Gly Pro Ala Ser Arg Arg Thr
 35 40 45
 Ser Ser Ser Gly Ser Ala Glu Pro Gly Ala Ala His Glu Met Lys Ser
 50 55 60
 Pro
 65

<210> 98

<211> 144

<212> PRT

<213> Homo sapiens

<400> 98

```

Pro Ser Ala Arg Ser Ser Pro His Ser Pro Trp Ser Ala Ala Ser Ser
 1           5           10           15
Trp Thr Ser Arg Arg Ser Ser Arg Asn Ser Leu Gly Arg Ala Pro Ser
          20           25           30
Leu Lys Arg Arg Ser Pro Ser Gly Glu Arg Arg Ser Leu Leu Ser Gly
          35           40           45
Glu Gly Gln Glu Ser Gln Asp Glu Glu Glu Ser Ser Glu Glu Glu Arg
          50           55           60
Ala Ser Pro Ala Gly Ser Asp His Arg His Arg Gly Ser Leu Glu Arg
65           70           75           80
Glu Ala Lys Ser Ser Phe Asp Leu Pro Asp Thr Leu Gln Val Pro Gly
          85           90           95
Leu His Arg Thr Ala Ser Gly Arg Gly Ser Ala Ser Glu His Gln Asp
          100          105          110
Cys Asn Gly Lys Ser Ala Ser Gly Arg Leu Ala Arg Ala Leu Arg Pro
          115          120          125
Asp Asp Pro Pro Leu Asp Gly Asp Asp Ala Asp Asp Glu Gly Asn Leu
          130          135          140

```

<210> 99
 <211> 34
 <212> PRT
 <213> Homo sapiens

```

<400> 99
Ser Lys Gly Glu Arg Val Arg Ala Trp Ile Arg Ala Arg Leu Pro Ala
 1           5           10           15
Cys Cys Leu Glu Arg Asp Ser Trp Ser Ala Tyr Ile Phe Pro Pro Gln
          20           25           30
Ser Arg

```

<210> 100
 <211> 41
 <212> PRT
 <213> Homo sapiens

```

<400> 100
Phe Arg Leu Leu Cys His Arg Ile Ile Thr His Lys Met Phe Asp His
 1           5           10           15
Val Val Leu Val Ile Ile Phe Leu Asn Cys Ile Thr Ile Ala Met Glu
          20           25           30
Arg Pro Lys Ile Asp Pro His Ser Ala
          35           40

```

<210> 101
 <211> 23
 <212> PRT
 <213> Homo sapiens

```

<400> 101
Glu Arg Ile Phe Leu Thr Leu Ser Asn Tyr Ile Phe Thr Ala Val Phe
 1           5           10           15
Leu Ala Glu Met Thr Val Lys
          20

```


<210> 102
 <211> 62
 <212> PRT
 <213> Homo sapiens

<400> 102
 Val Val Ala Leu Gly Trp Cys Phe Gly Glu Gln Ala Tyr Leu Arg Ser
 1 5 10 15
 Ser Trp Asn Val Leu Asp Gly Leu Leu Val Leu Ile Ser Val Ile Asp
 20 25 30
 Ile Leu Val Ser Met Val Ser Asp Ser Gly Thr Lys Ile Leu Gly Met
 35 40 45
 Leu Arg Val Leu Arg Leu Leu Arg Thr Leu Arg Pro Leu Arg
 50 55 60

<210> 103
 <211> 42
 <212> PRT
 <213> Homo sapiens

<400> 103
 Val Ile Ser Arg Ala Gln Gly Leu Lys Leu Val Val Glu Thr Leu Met
 1 5 10 15
 Ser Ser Leu Lys Pro Ile Gly Asn Ile Val Val Ile Cys Cys Ala Phe
 20 25 30
 Phe Ile Ile Phe Gly Ile Leu Gly Val Gln
 35 40

<210> 104
 <211> 42
 <212> PRT
 <213> Homo sapiens

<400> 104
 Leu Phe Lys Gly Lys Phe Phe Val Cys Gln Gly Glu Asp Thr Arg Asn
 1 5 10 15
 Ile Thr Asn Lys Ser Asp Cys Ala Glu Ala Ser Tyr Arg Trp Val Arg
 20 25 30
 His Lys Tyr Asn Phe Asp Asn Leu Gly Gln
 35 40

<210> 105
 <211> 30
 <212> PRT
 <213> Homo sapiens

<400> 105
 Ala Leu Met Ser Leu Phe Val Leu Ala Ser Lys Asp Gly Trp Val Asp
 1 5 10 15
 Ile Met Tyr Asp Gly Leu Asp Ala Val Gly Val Asp Gln Gln
 20 25 30

<210> 106
 <211> 64
 <212> PRT

<213> Homo sapiens

<400> 106

```

Pro Ile Met Asn His Asn Pro Trp Met Leu Leu Tyr Phe Ile Ser Phe
 1             5             10             15
Leu Leu Ile Val Ala Phe Phe Val Leu Asn Met Phe Val Gly Val Val
      20             25             30
Val Glu Asn Phe His Lys Cys Arg Gln His Gln Glu Glu Glu Glu Ala
      35             40             45
Arg Arg Arg Glu Glu Lys Arg Leu Arg Arg Leu Glu Lys Lys Arg Arg
 50             55             60

```

<210> 107

<211> 7

<212> PRT

<213> Homo sapiens

<400> 107

```

Ser Lys Glu Lys Gln Met Ala
 1             5

```

<210> 108

<211> 18

<212> PRT

<213> Homo sapiens

<400> 108

```

Asn Leu Met Leu Asp Asp Val Ile Ala Ser Gly Ser Ser Ala Ser Ala
 1             5             10             15
Ala Ser

```

<210> 109

<211> 51

<212> PRT

<213> Homo sapiens

<400> 109

```

Glu Ala Gln Cys Lys Pro Tyr Tyr Ser Asp Tyr Ser Arg Phe Arg Leu
 1             5             10             15
Leu Val His His Leu Cys Thr Ser His Tyr Leu Asp Leu Phe Ile Thr
      20             25             30
Gly Val Ile Gly Leu Asn Val Val Thr Met Ala Met Glu His Tyr Gln
      35             40             45
Gln Pro Gln
 50

```

<210> 110

<211> 37

<212> PRT

<213> Homo sapiens

<400> 110

```

Ile Leu Asp Glu Ala Leu Lys Ile Cys Asn Tyr Ile Phe Thr Val Ile
 1             5             10             15

```

Phe Val Leu Glu Ser Val Phe Lys Leu Val Ala Phe Gly Phe Arg Arg
 20 25 30
 Phe Phe Gln Asp Arg
 35

<210> 111
 <211> 44
 <212> PRT
 <213> Homo sapiens

<400> 111
 Trp Asn Gln Leu Asp Leu Ala Ile Val Leu Leu Ser Ile Met Gly Ile
 1 5 10 15
 Thr Leu Glu Glu Ile Glu Val Asn Ala Ser Leu Pro Ile Asn Pro Thr
 20 25 30
 Ile Ile Arg Ile Met Arg Val Leu Arg Ile Ala Arg
 35 40

<210> 112
 <211> 24
 <212> PRT
 <213> Homo sapiens

<400> 112
 Val Leu Lys Leu Leu Lys Met Ala Val Gly Met Arg Ala Leu Leu Asp
 1 5 10 15
 Thr Val Met Gln Ala Leu Pro Gln
 20

<210> 113
 <211> 26
 <212> PRT
 <213> Homo sapiens

<400> 113
 Val Gly Asn Leu Gly Leu Leu Phe Met Leu Leu Phe Phe Ile Phe Ala
 1 5 10 15
 Ala Leu Gly Val Glu Leu Phe Gly Asp Leu
 20 25

<210> 114
 <211> 41
 <212> PRT
 <213> Homo sapiens

<400> 114
 Glu Cys Asp Glu Thr His Pro Cys Glu Gly Leu Gly Arg His Ala Thr
 1 5 10 15
 Phe Arg Asn Phe Gly Met Ala Phe Leu Thr Leu Phe Arg Val Ser Thr
 20 25 30
 Gly Asp Asn Trp Asn Gly Ile Met Lys
 35 40

<210> 115
 <211> 118

<212> PRT

<213> Homo sapiens

<400> 115

```

Asp Thr Leu Arg Asp Cys Asp Gln Glu Ser Thr Cys Tyr Asn Thr Val
 1           5           10           15
Ile Ser Pro Ile Tyr Phe Val Ser Phe Val Leu Thr Ala Gln Phe Val
      20           25           30
Leu Val Asn Val Val Ile Ala Val Leu Met Lys His Leu Glu Glu Ser
      35           40           45
Asn Lys Glu Ala Lys Glu Glu Ala Glu Leu Glu Ala Glu Leu Glu Leu
      50           55           60
Glu Met Lys Thr Leu Ser Pro Gln Pro His Ser Pro Leu Gly Ser Pro
65           70           75           80
Phe Leu Trp Pro Gly Val Glu Gly Pro Asp Ser Pro Asp Ser Pro Lys
      85           90           95
Pro Gly Ala Leu His Pro Ala Ala His Ala Arg Ser Ala Ser His Phe
      100          105          110
Ser Leu Glu His Pro Thr
      115

```

<210> 116

<211> 48

<212> PRT

<213> Homo sapiens

<400> 116

```

Asp Arg Gln Leu Phe Asp Thr Ile Ser Leu Leu Ile Gln Gly Ser Leu
 1           5           10           15
Glu Trp Glu Leu Lys Leu Met Asp Glu Leu Ala Gly Pro Gly Gly Gln
      20           25           30
Pro Ser Ala Phe Pro Ser Ala Pro Ser Leu Gly Gly Ser Asp Pro Gln
      35           40           45

```

<210> 117

<211> 45

<212> PRT

<213> Homo sapiens

<400> 117

```

Ile Pro Leu Ala Glu Met Glu Ala Leu Ser Leu Thr Ser Glu Ile Val
 1           5           10           15
Ser Glu Pro Ser Cys Ser Leu Ala Leu Thr Asp Asp Ser Leu Pro Asp
      20           25           30
Asp Met His Thr Leu Leu Leu Ser Ala Leu Glu Ser Asn
      35           40           45

```

<210> 118

<211> 56

<212> PRT

<213> Homo sapiens

<400> 118

```

Met Gln Pro His Pro Thr Glu Leu Pro Gly Pro Asp Leu Leu Thr Val
 1           5           10           15

```

Arg Lys Ser Gly Val Ser Arg Thr His Ser Leu Pro Asn Asp Ser Tyr
 20 25 30
 Met Cys Arg His Gly Ser Thr Ala Glu Gly Pro Leu Gly His Arg Gly
 35 40 45
 Trp Gly Leu Pro Lys Ala Gln Ser
 50 55

<210> 119
 <211> 57
 <212> PRT
 <213> Homo sapiens

<400> 119
 Gly Ser Val Leu Ser Val His Ser Gln Pro Ala Asp Thr Ser Tyr Ile
 1 5 10 15
 Leu Gln Leu Pro Lys Asp Ala Pro His Leu Leu Gln Pro His Ser Ala
 20 25 30
 Pro Thr Trp Gly Thr Ile Pro Lys Leu Pro Pro Pro Gly Arg Ser Pro
 35 40 45
 Leu Ala Gln Arg Pro Leu Arg Arg Gln
 50 55

<210> 120
 <211> 22
 <212> PRT
 <213> Homo sapiens

<400> 120
 Ala Ala Ile Arg Thr Asp Ser Leu Asp Val Gln Gly Leu Gly Ser Arg
 1 5 10 15
 Glu Asp Leu Leu Ala Glu
 20

<210> 121
 <211> 79
 <212> PRT
 <213> Homo sapiens

<400> 121
 Val Ser Gly Pro Ser Pro Pro Leu Ala Arg Ala Tyr Ser Phe Trp Gly
 1 5 10 15
 Gln Ser Ser Thr Gln Ala Gln Gln His Ser Arg Ser His Ser Lys Ile
 20 25 30
 Ser Lys His Met Thr Pro Pro Ala Pro Cys Pro Gly Pro Glu Pro Asn
 35 40 45
 Trp Gly Lys Gly Pro Pro Glu Thr Arg Ser Ser Leu Glu Leu Asp Thr
 50 55 60
 Glu Leu Ser Trp Ile Ser Gly Asp Leu Leu Pro Pro Gly Gly Gln
 65 70 75

<210> 122
 <211> 143
 <212> PRT
 <213> Homo sapiens

<400> 122

Glu Glu Pro Pro Ser Pro Arg Asp Leu Lys Lys Cys Tyr Ser Val Glu
 1 5 10 15
 Ala Gln Ser Cys Gln Arg Arg Pro Thr Ser Trp Leu Asp Glu Gln Arg
 20 25 30
 Arg His Ser Ile Ala Val Ser Cys Leu Asp Ser Gly Ser Gln Pro His
 35 40 45
 Leu Gly Thr Asp Pro Ser Asn Leu Gly Gly Gln Pro Leu Gly Gly Pro
 50 55 60
 Gly Ser Arg Pro Lys Lys Lys Leu Ser Pro Pro Ser Ile Thr Ile Asp
 65 70 75 80
 Pro Pro Glu Ser Gln Gly Pro Arg Thr Pro Pro Ser Pro Gly Ile Cys
 85 90 95
 Leu Arg Arg Arg Ala Pro Ser Ser Asp Ser Lys Asp Pro Leu Ala Ser
 100 105 110
 Gly Pro Pro Asp Ser Met Ala Ala Ser Pro Ser Pro Lys Lys Asp Val
 115 120 125
 Leu Ser Leu Ser Gly Leu Ser Ser Asp Pro Ala Asp Leu Asp Pro
 130 135 140

<210> 123

<211> 79

<212> PRT

<213> Homo sapiens

<400> 123

Met Ala Glu Ser Ala Ser Pro Pro Ser Ser Ser Ala Ala Ala Pro Ala
 1 5 10 15
 Ala Glu Pro Gly Val Thr Thr Glu Gln Pro Gly Pro Arg Ser Pro Pro
 20 25 30
 Ser Ser Pro Pro Gly Leu Glu Glu Pro Leu Asp Gly Ala Asp Pro His
 35 40 45
 Val Pro His Pro Asp Leu Ala Pro Ile Ala Phe Phe Cys Leu Arg Gln
 50 55 60
 Thr Thr Ser Pro Arg Asn Trp Cys Ile Lys Met Val Cys Asn Pro
 65 70 75

<210> 124

<211> 37

<212> PRT

<213> Homo sapiens

<400> 124

Trp Phe Glu Cys Val Ser Met Leu Val Ile Leu Leu Asn Cys Val Thr
 1 5 10 15
 Leu Gly Met Tyr Gln Pro Cys Asp Asp Met Asp Cys Leu Ser Asp Arg
 20 25 30
 Cys Lys Ile Leu Gln
 35

<210> 125

<211> 45

<212> PRT

<213> Homo sapiens

<400> 125

Val Phe Asp Asp Phe Ile Phe Ile Phe Phe Ala Met Glu Met Val Leu
 1 5 10 15
 Lys Met Val Ala Leu Gly Ile Phe Gly Lys Lys Cys Tyr Leu Gly Asp
 20 25 30
 Thr Trp Asn Arg Leu Asp Phe Phe Ile Val Met Ala Gly
 35 40 45

<210> 126

<211> 32

<212> PRT

<213> Homo sapiens

<400> 126

Met Val Glu Tyr Ser Leu Asp Leu Gln Asn Ile Asn Leu Ser Ala Ile
 1 5 10 15
 Arg Thr Val Arg Val Leu Arg Pro Leu Lys Ala Ile Asn Arg Val Pro
 20 25 30

<210> 127

<211> 54

<212> PRT

<213> Homo sapiens

<400> 127

Ser Met Arg Ile Leu Val Asn Leu Leu Leu Asp Thr Leu Pro Met Leu
 1 5 10 15
 Gly Asn Val Leu Leu Leu Cys Phe Phe Val Phe Phe Ile Phe Gly Ile
 20 25 30
 Ile Gly Val Gln Leu Trp Ala Gly Leu Leu Arg Asn Arg Cys Phe Leu
 35 40 45
 Glu Glu Asn Phe Thr Ile
 50

<210> 128

<211> 105

<212> PRT

<213> Homo sapiens

<400> 128

Gln Gly Asp Val Ala Leu Pro Pro Tyr Tyr Gln Pro Glu Glu Asp Asp
 1 5 10 15
 Glu Met Pro Phe Ile Cys Ser Leu Ser Gly Asp Asn Gly Ile Met Gly
 20 25 30
 Cys His Glu Ile Pro Pro Leu Lys Glu Gln Gly Arg Glu Cys Cys Leu
 35 40 45
 Ser Lys Asp Asp Val Tyr Asp Phe Gly Ala Gly Arg Gln Asp Leu Asn
 50 55 60
 Ala Ser Gly Leu Cys Val Asn Trp Asn Arg Tyr Tyr Asn Val Cys Arg
 65 70 75 80
 Thr Gly Ser Ala Asn Pro His Lys Gly Ala Ile Asn Phe Asp Asn Ile
 85 90 95
 Gly Tyr Ala Trp Ile Val Ile Phe Gln
 100 105

<210> 129
 <211> 31
 <212> PRT
 <213> Homo sapiens

<400> 129
 Val Ile Thr Leu Glu Gly Trp Val Glu Ile Met Tyr Tyr Val Met Asp
 1 5 10 15
 Ala His Ser Phe Tyr Asn Phe Ile Tyr Phe Ile Leu Leu Ile Ile
 20 25 30

<210> 130
 <211> 104
 <212> PRT
 <213> Homo sapiens

<400> 130
 Val Gly Ser Phe Phe Met Ile Asn Leu Cys Leu Val Val Ile Ala Thr
 1 5 10 15
 Gln Phe Ser Glu Thr Lys Gln Arg Glu His Arg Leu Met Leu Glu Gln
 20 25 30
 Arg Gln Arg Tyr Leu Ser Ser Ser Thr Val Ala Ser Tyr Ala Glu Pro
 35 40 45
 Gly Asp Cys Tyr Glu Glu Ile Phe Gln Tyr Val Cys His Ile Leu Arg
 50 55 60
 Lys Ala Lys Arg Arg Ala Leu Gly Leu Tyr Gln Ala Leu Gln Ser Arg
 65 70 75 80
 Arg Gln Ala Leu Gly Pro Glu Ala Pro Ala Pro Ala Lys Pro Gly Pro
 85 90 95
 His Ala Lys Glu Pro Arg His Tyr
 100

<210> 131
 <211> 35
 <212> PRT
 <213> Homo sapiens

<400> 131
 His Gly Lys Thr Lys Gly Gln Gly Asp Glu Gly Arg His Leu Gly Ser
 1 5 10 15
 Arg His Cys Gln Thr Leu His Gly Pro Ala Ser Pro Gly Asn Asp His
 20 25 30
 Ser Gly Arg
 35

<210> 132
 <211> 142
 <212> PRT
 <213> Homo sapiens

<400> 132
 Glu Leu Cys Pro Gln His Ser Pro Leu Asp Ala Thr Pro His Thr Leu
 1 5 10 15
 Val Gln Pro Ile Pro Ala Thr Leu Ala Ser Asp Pro Ala Ser Cys Pro
 20 25 30

Cys	Cys	Gln	His	Glu	Asp	Gly	Arg	Arg	Pro	Ser	Gly	Leu	Gly	Ser	Thr
		35					40					45			
Asp	Ser	Gly	Gln	Glu	Gly	Ser	Gly	Ser	Gly	Ser	Ser	Ala	Gly	Gly	Glu
	50					55					60				
Asp	Glu	Ala	Asp	Gly	Asp	Gly	Ala	Arg	Ser	Ser	Glu	Asp	Gly	Ala	Ser
65					70					75					80
Ser	Glu	Leu	Gly	Lys	Glu	Glu	Glu	Glu	Glu	Glu	Gln	Ala	Asp	Gly	Ala
				85					90					95	
Val	Trp	Leu	Cys	Gly	Asp	Val	Trp	Arg	Glu	Thr	Arg	Ala	Lys	Leu	Arg
			100					105					110		
Gly	Ile	Val	Asp	Ser	Lys	Tyr	Phe	Asn	Arg	Gly	Ile	Met	Met	Ala	Ile
		115					120					125			
Leu	Val	Asn	Thr	Val	Ser	Met	Gly	Ile	Glu	His	His	Glu	Gln		
	130					135					140				

<210> 133

<211> 51

<212> PRT

<213> Homo sapiens

<400> 133

[illegible]

<210> 134

<211> 62

<212> PRT

<213> Homo sapiens

<400> 134

Ile	Trp	Glu	Ile	Val	Gly	Gln	Ala	Asp	Gly	Gly	Leu	Ser	Val	Leu	Arg
1				5					10					15	
Thr	Phe	Arg	Leu	Leu	Arg	Val	Leu	Lys	Leu	Val	Arg	Phe	Met	Pro	Ala
			20					25					30		
Leu	Arg	Arg	Gln	Leu	Val	Val	Leu	Met	Lys	Thr	Met	Asp	Asn	Val	Ala
		35					40					45			
Thr	Phe	Cys	Met	Leu	Leu	Met	Leu	Phe	Ile	Phe	Ile	Phe	Ser		
	50					55					60				

<210> 135

<211> 39

<212> PRT

<213> Homo sapiens

<400> 135

Ile	Leu	Gly	Met	His	Ile	Phe	Gly	Cys	Lys	Phe	Ser	Leu	Arg	Thr	Asp
1				5					10					15	
Thr	Gly	Asp	Thr	Val	Pro	Asp	Arg	Lys	Asn	Phe	Asp	Ser	Leu	Leu	Trp
			20					25					30		

Ala Ile Val Thr Val Phe Gln
35

<210> 136
<211> 52
<212> PRT
<213> Homo sapiens

<400> 136
Ile Leu Thr Gln Glu Asp Trp Asn Val Val Leu Tyr Asn Gly Met Ala
1 5 10 15
Ser Thr Ser Pro Trp Ala Ser Leu Tyr Phe Val Ala Leu Met Thr Phe
20 25 30
Gly Asn Tyr Val Leu Phe Asn Leu Leu Val Ala Ile Leu Val Glu Gly
35 40 45
Phe Gln Ala Glu
50

<210> 137
<211> 31
<212> PRT
<213> Homo sapiens

<400> 137
Gly Asp Ala Asn Arg Ser Tyr Ser Asp Glu Asp Gln Ser Ser Ser Asn
1 5 10 15
Ile Glu Glu Phe Asp Lys Leu Gln Glu Gly Leu Asp Ser Ser Gly
20 25 30

<210> 138
<211> 68
<212> PRT
<213> Homo sapiens

<400> 138
Asp Pro Lys Leu Cys Pro Ile Pro Met Thr Pro Asn Gly His Leu Asp
1 5 10 15
Pro Ser Leu Pro Leu Gly Gly His Leu Gly Pro Ala Gly Ala Ala Gly
20 25 30
Pro Ala Pro Arg Leu Ser Leu Gln Pro Asp Pro Met Leu Val Ala Leu
35 40 45
Gly Ser Arg Lys Ser Ser Val Met Ser Leu Gly Arg Met Ser Tyr Asp
50 55 60
Gln Arg Ser Leu
65

<210> 139
<211> 157
<212> PRT
<213> Homo sapiens

<400> 139
Ser Ser Ser Arg Ser Ser Tyr Tyr Gly Pro Trp Gly Arg Ser Ala Ala
1 5 10 15
Trp Ala Ser Arg Arg Ser Ser Trp Asn Ser Leu Lys His Lys Pro Pro

20 25 30
 Ser Ala Glu His Glu Ser Leu Leu Ser Ala Glu Arg Gly Gly Gly Ala
 35 40 45
 Arg Val Cys Glu Val Ala Ala Asp Glu Gly Pro Pro Arg Ala Ala Pro
 50 55 60
 Leu His Thr Pro His Ala His His Ile His His Gly Pro His Leu Ala
 65 70 75 80
 His Arg His Arg His His Arg Arg Thr Leu Ser Leu Asp Asn Arg Asp
 85 90 95
 Ser Val Asp Leu Ala Glu Leu Val Pro Ala Val Gly Ala His Pro Arg
 100 105 110
 Ala Ala Trp Arg Ala Ala Gly Pro Ala Pro Gly His Glu Asp Cys Asn
 115 120 125
 Gly Arg Met Pro Ser Ile Ala Lys Asp Val Phe Thr Lys Met Gly Asp
 130 135 140
 Arg Gly Asp Arg Gly Glu Asp Glu Glu Glu Ile Asp Tyr
 145 150 155

<210> 140
 <211> 34
 <212> PRT
 <213> Homo sapiens

<400> 140
 Thr Leu Cys Phe Arg Val Arg Lys Met Ile Asp Val Tyr Lys Pro Asp
 1 5 10 15
 Trp Cys Glu Val Arg Glu Asp Trp Ser Val Tyr Leu Phe Ser Pro Glu
 20 25 30
 Asn Arg

<210> 141
 <211> 41
 <212> PRT
 <213> Homo sapiens

<400> 141
 Phe Arg Val Leu Cys Gln Thr Ile Ile Ala His Lys Leu Phe Asp Tyr
 1 5 10 15
 Val Val Leu Ala Phe Ile Phe Leu Asn Cys Ile Thr Ile Ala Leu Glu
 20 25 30
 Arg Pro Gln Ile Glu Ala Gly Ser Thr
 35 40

<210> 142
 <211> 23
 <212> PRT
 <213> Homo sapiens

<400> 142
 Glu Arg Ile Phe Leu Thr Val Ser Asn Tyr Ile Phe Thr Ala Ile Phe
 1 5 10 15
 Val Gly Glu Met Thr Leu Lys
 20

<210> 143
 <211> 62
 <212> PRT
 <213> Homo sapiens

<400> 143
 Val Val Ser Leu Gly Leu Tyr Phe Gly Glu Gln Ala Tyr Leu Arg Ser
 1 5 10 15
 Ser Trp Asn Val Leu Asp Gly Phe Leu Val Phe Val Ser Ile Ile Asp
 20 25 30
 Ile Val Val Ser Leu Ala Ser Ala Gly Gly Ala Lys Ile Leu Gly Val
 35 40 45
 Leu Arg Val Leu Arg Leu Leu Arg Thr Leu Arg Pro Leu Arg
 50 55 60

<210> 144
 <211> 42
 <212> PRT
 <213> Homo sapiens

<400> 144
 Val Ile Ser Arg Ala Pro Gly Leu Lys Leu Val Val Glu Thr Leu Ile
 1 5 10 15
 Ser Ser Leu Lys Pro Ile Gly Asn Ile Val Leu Ile Cys Cys Ala Phe
 20 25 30
 Phe Ile Ile Phe Gly Ile Leu Gly Val Gln
 35 40

<210> 145
 <211> 42
 <212> PRT
 <213> Homo sapiens

<400> 145
 Leu Phe Lys Gly Lys Phe Tyr His Cys Leu Gly Val Asp Thr Arg Asn
 1 5 10 15
 Ile Thr Asn Arg Ser Asp Cys Met Ala Ala Asn Tyr Arg Trp Val His
 20 25 30
 His Lys Tyr Asn Phe Asp Asn Leu Gly Gln
 35 40

<210> 146
 <211> 30
 <212> PRT
 <213> Homo sapiens

<400> 146
 Ala Leu Met Ser Leu Phe Val Leu Ala Ser Lys Asp Gly Trp Val Asn
 1 5 10 15
 Ile Met Tyr Asn Gly Leu Asp Ala Val Ala Val Asp Gln Gln
 20 25 30

<210> 147
 <211> 64
 <212> PRT

<213> Homo sapiens

<400> 147

```

Pro Val Thr Asn His Asn Pro Trp Met Leu Leu Tyr Phe Ile Ser Phe
 1           5           10           15
Leu Leu Ile Val Ser Phe Phe Val Leu Asn Met Phe Val Gly Val Val
          20           25           30
Val Glu Asn Phe His Lys Cys Arg Gln His Gln Glu Ala Glu Glu Ala
          35           40           45
Arg Arg Arg Glu Glu Lys Arg Leu Arg Arg Leu Glu Lys Lys Arg Arg
 50           55           60

```

<210> 148

<211> 51

<212> PRT

<213> Homo sapiens

<400> 148

```

Lys Ala Gln Arg Leu Pro Tyr Tyr Ala Thr Tyr Cys His Thr Arg Leu
 1           5           10           15
Leu Ile His Ser Met Cys Thr Ser His Tyr Leu Asp Ile Phe Ile Thr
          20           25           30
Phe Ile Ile Cys Leu Asn Val Val Thr Met Ser Leu Glu His Tyr Asn
          35           40           45
Gln Pro Thr
 50

```

<210> 149

<211> 37

<212> PRT

<213> Homo sapiens

<400> 149

```

Ser Leu Glu Thr Ala Leu Lys Tyr Cys Asn Tyr Met Phe Thr Thr Val
 1           5           10           15
Phe Val Leu Glu Ala Val Leu Lys Leu Val Ala Phe Gly Leu Arg Arg
          20           25           30
Phe Phe Lys Asp Arg
          35

```

<210> 150

<211> 44

<212> PRT

<213> Homo sapiens

<400> 150

```

Trp Asn Gln Leu Asp Leu Ala Ile Val Leu Leu Ser Val Met Gly Ile
 1           5           10           15
Thr Leu Glu Glu Ile Glu Ile Asn Ala Ala Leu Pro Ile Asn Pro Thr
          20           25           30
Ile Ile Arg Ile Met Arg Val Leu Arg Ile Ala Arg
          35           40

```

<210> 151

<211> 24

<212> PRT

<213> Homo sapiens

<400> 151

Val Leu Lys Leu Leu Lys Met Ala Thr Gly Met Arg Ala Leu Leu Asp
 1 5 10 15
 Thr Val Val Gln Ala Leu Pro Gln
 20

<210> 152

<211> 26

<212> PRT

<213> Homo sapiens

<400> 152

Val Gly Asn Leu Gly Leu Leu Phe Met Leu Leu Phe Phe Ile Tyr Ala
 1 5 10 15
 Ala Leu Gly Val Glu Leu Phe Gly Lys Leu
 20 25

<210> 153

<211> 41

<212> PRT

<213> Homo sapiens

<400> 153

Val Cys Asn Asp Glu Asn Pro Cys Glu Gly Met Ser Arg His Ala Thr
 1 5 10 15
 Phe Glu Asn Phe Gly Met Ala Phe Leu Thr Leu Phe Gln Val Ser Thr
 20 25 30
 Gly Asp Asn Trp Asn Gly Ile Met Lys
 35 40

<210> 154

<211> 113

<212> PRT

<213> Homo sapiens

<400> 154

Asp Thr Leu Arg Asp Cys Thr His Asp Glu Arg Ser Cys Leu Ser Ser
 1 5 10 15
 Leu Gln Phe Val Ser Pro Leu Tyr Phe Val Ser Phe Val Leu Thr Ala
 20 25 30
 Gln Phe Val Leu Ile Asn Val Val Val Ala Val Leu Met Lys His Leu
 35 40 45
 Asp Asp Ser Asn Lys Glu Ala Gln Glu Asp Ala Glu Met Asp Ala Glu
 50 55 60
 Leu Glu Leu Glu Met Ala His Gly Leu Gly Pro Gly Pro Arg Leu Pro
 65 70 75 80
 Thr Gly Ser Pro Gly Ala Pro Gly Arg Gly Pro Gly Gly Ala Gly Gly
 85 90 95
 Gly Gly Asp Thr Glu Gly Gly Leu Cys Arg Arg Cys Tyr Ser Pro Ala
 100 105 110
 Gln

<210> 155
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 155
 Glu Asn Leu Trp Leu Asp Ser Val Ser Leu Ile Ile Lys
 1 5 10

<210> 156
 <211> 36
 <212> PRT
 <213> Homo sapiens

<400> 156
 Asp Ser Leu Glu Gly Glu Leu Thr Ile Ile Asp Asn Leu Ser Gly Ser
 1 5 10 15
 Ile Phe His His Tyr Ser Ser Pro Ala Gly Cys Lys Lys Cys His His
 20 25 30
 Asp Lys Gln Glu
 35

<210> 157
 <211> 41
 <212> PRT
 <213> Homo sapiens

<400> 157
 Val Gln Leu Ala Glu Thr Glu Ala Phe Ser Leu Asn Ser Asp Arg Ser
 1 5 10 15
 Ser Ser Ile Leu Leu Gly Asp Asp Leu Ser Leu Glu Asp Pro Thr Ala
 20 25 30
 Cys Pro Pro Gly Arg Lys Asp Ser Lys
 35 40

<210> 158
 <211> 55
 <212> PRT
 <213> Homo sapiens

<400> 158
 Gly Glu Leu Asp Pro Pro Glu Pro Met Arg Val Gly Asp Leu Gly Glu
 1 5 10 15
 Cys Phe Phe Pro Leu Ser Ser Thr Ala Val Ser Pro Asp Pro Glu Asn
 20 25 30
 Phe Leu Cys Glu Met Glu Glu Ile Pro Phe Asn Pro Val Arg Ser Trp
 35 40 45
 Leu Lys His Asp Ser Ser Gln
 50 55

<210> 159
 <211> 66
 <212> PRT
 <213> Homo sapiens

<400> 159

Ala Pro Pro Ser Pro Phe Ser Pro Asp Ala Ser Ser Pro Leu Leu Pro
 1 5 10 15
 Met Pro Ala Glu Phe Phe His Pro Ala Val Ser Ala Ser Gln Lys Gly
 20 25 30
 Pro Glu Lys Gly Thr Gly Thr Gly Thr Leu Pro Lys Ile Ala Leu Gln
 35 40 45
 Gly Ser Trp Ala Ser Leu Arg Ser Pro Arg Val Asn Cys Thr Leu Leu
 50 55 60
 Arg Gln
 65

<210> 160

<211> 7

<212> PRT

<213> Homo sapiens

<400> 160

Val Pro Thr Pro Pro Arg Pro
 1 5

<210> 161

<211> 214

<212> PRT

<213> Homo sapiens

<400> 161

Ala Thr Gly Ser Asp Thr Ser Leu Asp Ala Ser Pro Ser Ser Ser Ala
 1 5 10 15
 Gly Ser Leu Gln Thr Thr Leu Glu Asp Ser Leu Thr Leu Ser Asp Ser
 20 25 30
 Pro Arg Arg Ala Leu Gly Pro Pro Ala Pro Ala Pro Gly Pro Arg Ala
 35 40 45
 Gly Leu Ser Pro Ala Ala Arg Arg Arg Leu Ser Leu Arg Gly Arg Gly
 50 55 60
 Leu Phe Ser Leu Arg Gly Leu Arg Ala His Gln Arg Ser His Ser Ser
 65 70 75 80
 Gly Gly Ser Thr Ser Pro Gly Cys Thr His His Asp Ser Met Asp Pro
 85 90 95
 Ser Asp Glu Glu Gly Arg Gly Gly Ala Gly Gly Gly Ala Gly Ser
 100 105 110
 Glu His Ser Glu Thr Leu Ser Ser Leu Ser Leu Thr Ser Leu Phe Cys
 115 120 125
 Pro Pro Pro Pro Pro Pro Ala Pro Gly Leu Thr Pro Ala Arg Lys Phe
 130 135 140
 Ser Ser Thr Ser Ser Leu Ala Ala Pro Gly Arg Pro His Ala Ala Ala
 145 150 155 160
 Leu Ala His Gly Leu Ala Arg Ser Pro Ser Trp Ala Ala Asp Arg Ser
 165 170 175
 Lys Asp Pro Pro Gly Arg Ala Pro Leu Pro Met Gly Leu Gly Pro Leu
 180 185 190
 Ala Pro Pro Pro Gln Pro Leu Pro Gly Glu Leu Glu Pro Gly Asp Ala
 195 200 205
 Ala Ser Lys Arg Lys Arg
 210

<210> 162
 <211> 18
 <212> PRT
 <213> Homo sapiens

<400> 162
 Asp Leu Met Leu Asp Asp Val Ile Ala Ser Gly Ser Ser Ala Ser Ala
 1 5 10 15
 Ala Ser

<210> 163
 <211> 51
 <212> PRT
 <213> Homo sapiens

<400> 163
 Lys Ala Gln Cys Lys Pro Tyr Tyr Ser Asp Tyr Ser Arg Phe Arg Leu
 1 5 10 15
 Leu Val His His Leu Cys Thr Ser His Tyr Leu Asp Leu Phe Ile Thr
 20 25 30
 Gly Val Ile Gly Leu Asn Val Val Thr Met Ala Met Glu His Tyr Gln
 35 40 45
 Gln Pro Gln
 50

<210> 164
 <211> 142
 <212> PRT
 <213> Homo sapiens

<400> 164
 Gln Leu Cys Pro Gln His Ser Pro Leu Asp Ala Thr Pro His Thr Leu
 1 5 10 15
 Val Gln Pro Ile Pro Ala Thr Leu Ala Ser Asp Pro Ala Ser Cys Pro
 20 25 30
 Cys Cys Gln His Glu Asp Gly Arg Arg Pro Ser Gly Leu Gly Ser Thr
 35 40 45
 Asp Ser Gly Gln Glu Gly Ser Gly Ser Gly Ser Ser Ala Gly Gly Glu
 50 55 60
 Asp Glu Ala Asp Gly Asp Gly Ala Arg Ser Ser Glu Asp Gly Ala Ser
 65 70 75 80
 Ser Glu Leu Gly Lys Glu Glu Glu Glu Glu Gln Ala Asp Gly Ala
 85 90 95
 Val Trp Leu Cys Gly Asp Val Trp Arg Glu Thr Arg Ala Lys Leu Arg
 100 105 110
 Gly Ile Val Asp Ser Lys Tyr Phe Asn Arg Gly Ile Met Met Ala Ile
 115 120 125
 Leu Val Asn Thr Val Ser Met Gly Ile Glu His His Glu Gln
 130 135 140